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Hereditary Breast and Ovarian Cancer Syndrome (HBOC) is caused by BRCA1/2 gene 
mutations. BRCA1/2 mutations are observed in 1 in 800 in the non-Ashkenazi Jewish population, 
while an individual of Ashkenazi Jewish (AJ) ancestry has an a priori risk of 1 in 40. This pilot 
study was designed to document common beliefs about cancer genetics services (CGS) and to 
identify the preferred methods of communication regarding cancer risks and inherited cancer 
predispositions to the AJ population. Participants were recruited on a voluntary basis from the 
Jewish community of Pittsburgh, PA to participate in an informal information session about 
cancer genetics at a local synagogue. Sixteen participants completed surveys with questions 
pertaining to basic genetics knowledge and beliefs regarding inherited cancer risks, genetic 
counseling and genetic testing for HBOC before and after the information session, thus allowing 
researchers to identify changes in genetic knowledge, as well as differences in perceptions about 
cancer genetics and CGS. Findings revealed that the main motivation to pursue CGS is if an 
individual perceives they are at a high-risk status to develop cancer based on personal or family 
history of cancer. The data shows that AJ individuals are aware of cancer genetics and risks 
associated with their ancestry, but do not pursue or participate in CGS due to a perception of 
lacking knowledge about general cancer genetics. Although 56.25% of respondents reported that 
their health care providers are not aware of their AJ ancestry, 75% reported that they preferred to 
learn of cancer genetics information and CGS through a healthcare provider or physician. 
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Between the pre- and post-information session surveys, analysis of the knowledge-based 
questions showed that the average correct response rate for every question increased (77% to 
94%). The results of this study have important public health implications because they encourage 
the idea that a future preferred service delivery model for AJ population-specific genetic 
counseling may include informal community-based cancer genetics information sessions prior to 
traditional genetic counseling, thus allowing traditional counseling to focus on personalized risk 
assessment, benefits and limitations of testing, and potential psychosocial issues that are unique 
to each individual or family.  
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1.0  INTRODUCTION 
This study was undertaken to supplement current literature about cancer genetic counseling 
services (CGS) in the Ashkenazi Jewish (AJ) population and to determine if there are unique 
motivations for and perceived barriers to AJ individuals obtaining CGS.  
For almost two decades, genetic counseling and testing for Hereditary Breast and Ovarian 
Cancer Syndrome (HBOC) has provided thousands of families with information about cancer 
risk and options for risk reduction and prevention. Mutations in BRCA1 and BRCA2 account for 
approximately 84% of hereditary breast cancers and over 90% of hereditary ovarian cancers 
(Petrucelli et al., 2010). BRCA1/2 gene mutations are observed in approximately 1 in 400 to 1 in 
800 in the general population, while an individual of AJ ancestry has an a priori risk of 1 in 40, 
or 2.5% (Claus et al., 1996; Ford et al., 1994; Whittemore et al., 1997; Petrucelli et al., 2010; 
Foulkes, 2008; Metcalfe et al., 2010). Increasingly, BRCA testing is helping individuals at 
increased risk make decisions regarding cancer surveillance and prevention, with the goal of 
reducing the incidence and mortality associated with these cancers.  
According to the United Jewish Federation (UJF) 2002 Pittsburgh Jewish Community 
Study, there were approximately 54,000 individuals of AJ ancestry living in 20,900 Pittsburgh 
metropolitan area households (UJFGP, 2002). Given the statistics from the UJF study and 
statistically expecting 2.5% to carry a BRCA1/2 gene mutation, the expected number of AJ 
individuals in Pittsburgh with a BRCA1/2 mutation would equal 1,305.  
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Several published studies have focused on the beliefs of AJ individuals regarding genetic 
testing for HBOC; however, studies focusing specifically on the unique motivations for and 
perceived barriers to AJ individuals obtaining genetic counseling are limited. This study was 
designed to facilitate awareness of CGS, document common beliefs about CGS in the AJ 
population and identify preferred methods of communication regarding cancer risks and 
inherited cancer predispositions in the AJ population. The primary aim of this research is to aide 
in the identification of a preferred service delivery model for genetic counseling specific to the 
AJ population with respect to HBOC.  
1.1 SPECIFIC AIMS 
Specific Aim 1:  To identify the current awareness, as well as facilitate awareness, of 
cancer genetic counseling services in the Ashkenazi Jewish population in 
the Pittsburgh area. 
Hypothesis:   Individuals of Ashkenazi Jewish ancestry are not aware of cancer genetic  
counseling services. 
Plan:   Surveys will inquire about participant’s knowledge (or lack of knowledge) 
   of cancer genetic counseling services, including the initial source of 
   knowledge, previous experiences with genetic counseling and any prior 
awareness of available genetic testing for hereditary cancer predisposition  
syndromes.  
Specific Aim 2:  To identify the unique motivations for and perceived barriers to Ashkenazi 
Jewish individuals obtaining cancer genetic counseling services. 
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Hypothesis:  Personal perception of increased risk to develop cancer based on family 
history or Ashkenazi Jewish ancestry is the main motivator for seeking 
cancer genetic counseling services. Lack of information about cancer 
genetics, cancer risk and recommendations for genetic counseling is the 
main barrier to obtaining cancer genetic counseling services.   
Plan:   Survey responses to questions specifically inquiring about motivations for  
and barriers to obtaining cancer genetic services will be analyzed to try 
and identify common trends.   
Specific Aim 3: To identify the preferred methods of communicating information about 
   inherited predispositions to cancer to the Ashkenazi Jewish population. 
Hypothesis:   Individuals of Ashkenazi Jewish ancestry often have close family  
relationships; therefore, communication between informed relatives may 
be the preferred strategy for disseminating information about cancer 
genetic services. 
Plan:   Survey responses to questions specifically inquiring about communication 
   preferences and main sources of support will be analyzed to see if a 
   preferred communication method emerges. 
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1.2 BACKGROUND OF HEREDITARY BREAST AND OVARIAN CANCER 
In the United States, approximately half of all men and one third of all women will develop 
cancer during their lifetime (ACS1, 2011). A carcinogenic event can occur as the result of a 
germline or somatic mutation in a major cancer predisposition gene that is responsible for cell 
growth or repair, including: proto-oncogenes, tumor suppressor genes and DNA repair genes 
(Schneider, 2002; Trepanier et al., 2004). 
 Breast cancer is the second most common type of cancer in American women, behind only 
skin cancer. In the general population, breast cancer occurs in approximately 1 in 8 women 
(12%) with a median age of onset of 61 years (ACS2, 2011). Generally, the 5-year survival rate 
for breast cancer in females ranges from 88% (stage I) to 15% (stage IV) (ACS2, 2011). Male 
breast cancer is rare, accounting for approximately 1% of all breast cancers. The 5-year survival 
rate for breast cancer in males ranges from 96% (stage I) to 24% (stage IV) (ACS2, 2011).   
 Ovarian cancer is the ninth most common cancer in American women, not including skin 
cancer (ACS3, 2011). In the general population, ovarian cancer occurs in approximately 1 in 70 
women (1.5%) and typically develops after the age of 60 (ACS3, 2011). Generally, the 5-year 
survival rate for ovarian cancer ranges from 89% (stage I) to 18% (stage IV) (ACS3, 2011).   
           1.2.1 Categories of Cancer  
As illustrated in Figure 1, there are three main etiologies of cancer development: a sporadic 
occurrence, familial predisposition and hereditary predisposition (Claus et al., 1996). 
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Figure 1. Categories of Cancer 
 
 The majority of cancer, approximately 60%, is sporadic, or occurs by chance. Sporadic 
cancers occur as the result of somatic mutations in major cancer predisposition genes (Trepanier 
et al., 2004). Somatic mutations are acquired, resulting from lifestyle factors and environmental 
exposures during the normal aging process, or caused by unknown factors (Amos, 1994; Chen et 
al., 1994; Trepanier et al., 2004). There are many lifestyle factors and environmental exposures 
that influence cancer development. The most significant risk factors for the development of 
breast cancer are gender (being female) and aging (ACS2, 2011). Additional risk factors (and risk 
modifiers) for the development of breast cancer in the general population include:  
• Hormonal Factors 
o Early menarche (<12 years) and older age at menopause (> 55 years) 
(Hulka et al., 2001; Kelsey et al., 1993) 
o Recent, long-term hormone replacement therapy (Chlebowski et al., 2010; 
Collaborative Group on Hormonal Factors in Breast Cancer, 1997; Beral 
et al., 2011) 
 
Familial 
Hereditary 
Sporadic 
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o Age at first live birth (>30 years) and number of pregnancies (nulliparity) 
(Kelsey et al., 1993; Lambe et al., 1994) 
o Oral contraceptive use (risk returns to baseline 10 years after use) 
(Collaborative Group on Hormonal Factors in Breast Cancer, 1996) 
o Breastfeeding has been shown to decrease breast cancer risk (4.3% for 
every 12 months of breastfeeding), with greater benefit associated with 
longer duration (Collaborative Group on Hormonal Factors in Breast 
Cancer, 2002) 
• Clinical Factors 
o Benign breast conditions 
§ Lobular carcinoma in situ (LCIS) can increase breast cancer risk 8 
to 10 times that of women of average-risk (Oppong et al., 2011) 
§ Atypical ductal/lobular hyperplasia can increase breast cancer risk 4 
to 5 times that of women of average-risk (Hartmann et al., 2005; 
Tamimi et al., 2005; Ashbeck et al., 2007) 
§ High breast tissue density can increase breast cancer risk 4 to 6 
times that of women with less dense breasts (Cummings et al., 
2009; Ginsburg et al., 2008; Boyd et al., 2007; McCormack et al., 
2006) 
o High bone density post menopause (Chen et al., 2008; Zmuda et al., 2001; 
Zhang et al., 1997; Cauley et al., 1996; Kerlikowske et al., 2005) 
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o Obesity can increase the risk of postmenopausal breast cancer; however, 
obesity is considered protective against premenopausal breast cancer 
(ACS2, 2011) 
o Personal history of breast cancer (especially early-onset, <40 years of age) 
can increase the risk for subsequent breast cancer 4.5 times that of women 
without a personal history (ACS2, 2011) 
• Exposures 
o High-dose radiation between the ages of 10-30 years, most often related to 
the treatment of lymphoma (ACS2, 2011) 
o Exposure to diethylstilbestrol (DES) in utero increases breast cancer risk 
by 3.9% (Hoover et al., 2011) 
o Alcohol use (more than 2 drinks per day) can increase breast cancer risk 
by 21% (Singletary et al., 2001) 
• Family history (ACS2, 2011; Trepanier et al., 2004; Chen et al., 1994) 
o The risk of breast cancer is 1.7 times higher for women with one 1st-
degree female relative with breast cancer, nearly 3 times higher for women 
with two relatives with breast cancer and nearly 4 times higher for women 
with three or more relatives with breast cancer (Collaborative Group on 
Hormonal Factors in Breast Cancer, 2001) 
o Family history of ovarian cancer (ACS2, 2011) 
o Hereditary cancer syndromes predisposing to breast cancer 
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Figure 2 illustrates the comparison between the relative risks associated with specific 
hormonal, clinical and family history factors that can contribute to the development of breast 
cancer.  
 
Figure 2. Comparison of Risk Factors for Breast Cancer (Relative Risk) 
 
 Environmental and lifestyle risk factors (and risk modifiers) for ovarian cancer in the 
general population include:  
• Hormonal Factors 
o Age of first pregnancy (a pregnancy >35 years of age is twice as 
protective against ovarian cancer as a pregnancy <25 years of age) and 
total number of pregnancies (one pregnancy lowers risk by as much as 
33% and the reduction in risk increases with each additional pregnancy) 
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(Whittemore et al., 1992; Risch et al., 1983; Cramer et al., 1983; Joly et 
al., 1974; Hildreth et al., 1981; Whiteman et al., 2003)  
o Infertility is associated with a 2-fold increased risk of ovarian cancer; 
however, it is unclear whether this risk is due to infertility alone or 
conflicting data on the impact of fertility drugs (Tworoger et al., 2007; 
Rossing et al., 2004; Jensen et al., 2009) 
o Breastfeeding (<18 months) may decrease the risk for ovarian cancer by 
as much as 34% (Danforth et al., 2007) 
o Oral contraceptive use is associated with a 30 to 50% decreased risk of 
ovarian cancer if taken for three or more years (Whittemore et al., 1992; 
Weiss et al., 1996; Beral et al., 2008)  
• Clinical Factors 
o Increasing age (> 50% of all cases occur in women over the age of 63 
years) (ACS3, 2011) 
o Obesity (Olsen et al., 2007) 
o Long-standing history of ovarian endometriosis (Munksgaard et al., 2011) 
o Long-standing history of Pelvic Inflammatory Disease (Lin et al., 2011) 
o Regular paracetamol use is associated with a decreased risk for ovarian 
cancer (Bonovas et al., 2006)  
o Hysterectomy and tubal ligation are associated with a 34% reduction in 
the risk of developing ovarian cancer (Whittemore et al., 1992; Cibula et 
al., 2011)   
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• Exposures 
o Talcum powder use (in the perineal area) increases risk by 33% due to 
contents of asbestos (Cramer et al., 1982; Chang et al., 1997; Harlow et 
al., 1992; Huncharek et al., 2003) 
• Family History (ACS3, 2011) 
o The risk of ovarian cancer is 3.6 times higher for women with one 1st- 
degree relatives with ovarian cancer and 2.9 times higher for women with 
one 2nd- degree relative with ovarian cancer (Schildkraut et al., 1989) 
o Hereditary cancer syndromes predisposing to ovarian cancer   
  Approximately 30% of cancers are “familial”, meaning there is a clustering of cancer 
within a family or more cases than would be expected by chance. There is no single explanation 
for these cancers, but they probably result from multiple factors in the environment (in the 
absence of an identifiable carcinogenic exposure) and multiple genetic factors interacting over 
time (Trepanier et al., 2004). Familial cancers tend to have a variable age of onset, but may be 
slightly younger than the general population and are multifactorial in origin. Familial cancer 
could also represent a clustering of sporadic occurrences (Berliner et al., 2007).  
Approximately 7 to 10% of cancers are hereditary, or are caused by inheriting a single 
gene mutation. Inherited germline mutations in tumor suppressor genes, as well as the 
acquisition of somatic mutations in the same cell, cause hereditary cancer to develop (Foulkes, 
2008). This phenomenon, first described by Dr. Alfred Knudson in 1971, is known as the Two 
Hit Hypothesis. Knudson theorized that individuals with a germline mutation (first hit) would 
only need to acquire a somatic mutation in that cell (second hit) to lose control of cell division 
and lead to carcinogenesis (Knuden, 1971). Knudson’s hypothesis proved true and led to the 
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realization that hereditary cancers caused by mutations in specific genes can be associated with 
some characteristic features, including early age of cancer onset, related cancers found in the 
same family (in the same bloodline) and unusual or rare tumors (NCCN, 2011).  
            1.2.2 Hereditary Breast and Ovarian Cancer Syndrome (HBOC) 
Hereditary Breast and Ovarian Cancer Syndrome, caused by mutations in the tumor suppressor 
genes BRCA1 and BRCA2, accounts for approximately 3-5% of all breast cancers and 10% of all 
ovarian cancers (Petrucelli et al., 2010; ACOG, 2009). BRCA1/2 mutations occur in all ethnic 
and racial populations (Claus et al., 1996; Ford et al., 1994; Whittemore et al., 1997).  
 
Figure 3. Gene Mutations Leading to Hereditary Breast and Ovarian Cancer 
As illustrated above in Figure 3, mutations in BRCA1/2 account for approximately 84% 
of hereditary cases of breast cancer, and approximately 16% of HBOC cases are attributed to 
genes that have yet-to-be discovered (Ford et al., 1998; Robson et al., 2001; Risch et al., 2006; 
Rubin et al., 1998; Claus et al., 1996; ACOG, 2009). Features suggestive of HBOC include 
early-onset breast cancer (<50 years), bilateral breast cancer, ovarian cancer, breast and ovarian 
cancer in the same individual and male breast cancer.  
32% BRCA2 
52% BRCA1 
16% Other Genes 
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           1.2.2.1 The BRCA Genes  
The BRCA1 gene, located on chromosome 17q21, was isolated in 1990 and then found to be 
associated with HBOC in 1994 (Hall et al., 1990; Miki et al., 1994). BRCA1 encodes the breast 
cancer type 1 susceptibility protein that interacts with other proteins involved in cell cycle 
progression, gene transcription regulation, DNA damage response and ubiquitination (Deng, 
2006; Rosen et al., 2006, Hall et al., 1990). The BRCA2 gene, located on chromosome 13q12.3, 
was identified in 1995 (Wooster et al., 1995). BRCA2 encodes the breast cancer type 2 
susceptibility protein that is involved in the DNA repair process of double-strand breaks (Zhang 
et al., 1998; Venkitaraman, 2001; Wooster et al., 1994).  
There are thousands of unique reported mutations in BRCA1/2 that can lead to an HBOC-
phenotype. Over 1,600 mutations have been identified in BRCA1 and over 1,800 mutations have 
been identified in BRCA2 (Petrucelli et al., 2010). The most common types of deleterious 
mutations are those that result in missing, abnormal or nonfunctional proteins (nonsense), which 
account for approximately 88% of the mutations in BRCA1/2. Deletions and duplications account 
for the remaining 12% of deleterious mutations seen in BRCA1/2 (Walsh et al., 2006). 
           1.2.2.2 Phenotypes Associated with BRCA Mutations  
An abundance of studies have been conducted to understand penetrance associated with BRCA1 
and BRCA2 mutations. As seen in Table 1, multiple studies have shown that BRCA1/2 mutations 
have the most significant impact on breast and ovarian cancer risk. The lifetime risk of breast 
and ovarian cancer for a woman with a BRCA mutation has a range of 50 to 87% and 27 to 44%, 
respectively. The range of risk is a result of incomplete penetrance in some families. It is known 
that the risk of both breast and ovarian cancer is higher in individuals with BRCA1 mutations 
than with BRCA2 mutations (Antoniou et al., 2003).  
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Table 1. Lifetime Cancer Risks Associated with BRCA1/2 Mutations (Breast and Ovary) 
 
Cancer 
 
Population Risk 
 
BRCA1/2 Mutation 
 
Breast 
 
8-12%1 
 
50-87%4 
 
Ovary 
 
<2%2 
 
27-44%5 
 
2nd Breast 
 
<10%3 
 
2-3% per year6
1. ACS4, 2012 2. ACS3, 2011 3. ACS4, 2012 4, Ford et al., 1994 5. Ford et al., 1998 6. Breast Cancer Linkage Consortium, 1999 
7.Thompson et al., 2001   
 
Several additional studies have revealed that mutations in the BRCA genes can increase 
the lifetime risk for other types of cancer (Thull et al., 2004). Carriers of BRCA1 mutations can 
have an increased risk for cancers of the fallopian tube, uterus, cervix, prostate, pancreas, 
stomach and colon (Ford et al., 1998; Thompson et al., 2002). Carriers of BRCA2 mutations can 
have an increased risk for early-onset prostate cancer (before age 55), male breast cancer, 
melanoma, ocular melanoma and cancer of the pancreas, stomach, gallbladder and bile duct 
(Breast Cancer Linkage Consortium, 1999; Easton et al., 1997; Edwards et al., 2003). 
Many studies have been conducted to understand specific tumor pathology associated 
with BRCA1 and BRCA2 mutations. BRCA1-related breast tumors are most likely to be of high 
histologic grade (medullary histopathology) and are most likely to be classified as “triple 
negative” breast tumors, meaning that the tumor is estrogen and progesterone receptor-negative 
and does not demonstrate HER2/neu overexpression (Rakha et al., 2008; Petrucelli et al., 2010). 
BRCA2-related breast tumors do not seem to have a characteristic histopathology or 
classification, although the information regarding BRCA2-related breast tumors is limited 
(Petrucelli et al., 2010). The only ovarian lesions associated with BRCA1 and BRCA2 mutations 
are invasive, non-mucinous epithelial ovarian tumors of high histologic grade and serous  
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adenocarcinomas (Petrucelli et al., 2010). The most commonly associated ovarian tumors are 
serous papillary cystadenocarcinomas. Benign ovarian cysts (e.g. cystadenomas) and borderline 
tumors (or tumors of low malignant potential) are not part of the BRCA spectrum.  
           1.2.2.3 Ashkenazi Jewish (AJ) Founder Mutations  
The majority of hereditary diseases occur across ethnic and racial populations, although there are 
some populations in which they occur at a much higher prevalence than expected (Petrucelli et 
al., 2010; Claus et al., 1996; Ford et al., 1994; Whittemore et al., 1997). This is known as the 
‘founder effect’, or “the chance presence of certain mutant alleles among the ‘founders’ or 
ancestors who emigrated to [a particular location] and whose descendants constitute [a certain 
ethnic or racial group]” (Charrow, 2004).  
Several hereditary diseases occur at a higher frequency in the AJ population due to 
common founder mutations. Individuals of AJ ancestry originated from Eastern Europe, 
particularly: Hungary, Poland, Russia, Lithuania, Italy, Portugal and Spain. It is hypothesized 
that the AJ founder effect began in 1500 CE, when Christians ruled medieval Europe. During 
that time, Jewish individuals were the minority and as a result were genetically and culturally 
isolated (Hamel et al., 2011). Population genetics concepts such as population bottleneck effect, 
positive assortative mating, admixture and genetic drift all try to explain various founder 
mutations that occur in the AJ population (Im et al., 2011; Hamel et al., 2011; Risch et al., 1995, 
2003; Ostrer, 2001).  
With an estimated prevalence of 1 in 40 or 2.5%, individuals of AJ ancestry are at a 
significantly increased risk over the general population to have BRCA1/2 gene mutations due to 
founder effects (Petrucelli et al., 2010; Foulkes, 2008; Metcalfe et al., 2010). There are three 
specific HBOC-related AJ founder mutations including two in BRCA1 (187delAG and 5385insC, 
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also known as 185delAG and 5382insC, respectively) and one in BRCA2 (6174delT) (Roa et al., 
1996). In individuals of AJ ancestry, the 187delAG mutation and 5385insC mutation in BRCA1 
have been estimated to occur with a frequency of about 1.1% and 0.1-0.15%, respectively (John 
et al., 2007; Oddoux et al., 1996; Struewing et al., 1995; Roa et al., 1996). The 6174delT 
mutation in BRCA2 has been estimated to occur with a frequency of about 1.5% in individuals 
with AJ ancestry (Struewing et al., 1997; Oddoux et al., 1996; Struewing et al., 1995; Roa et al., 
1996). Table 2 outlines the estimated cancer risks associated with the three HBOC-related 
founder mutations in the AJ population. 
Table 2. Lifetime Cancer Risks Associated with BRCA1/2 Mutations (AJ Founder Mutations) 
 
 
Cancer 
 
187delAG 
 
5383insC 
 
6174delT 
 
Breast 
 
64% 
 
67% 
 
43% 
 
Ovary 
 
14% 
 
33% 
 
20% 
adapted from Antoniou et al., 2005 
  
In addition to the three founder mutations in BRCA1/2, there are almost 20 different 
genetic diseases that have associated AJ founder mutations. The most commonly known 
syndromes associated with AJ ethnicity are different from HBOC in regards to inheritance 
pattern, penetrance and onset. While HBOC is inherited in an autosomal dominant pattern, the 
common syndromes associated with AJ ethnicity are inherited in an autosomal recessive pattern 
and predominately occur during childhood. Some of the syndromes associated with AJ ethnicity 
and their associated founder mutations are outlined in Table 3, which was adapted from the 
Victor Centers for Jewish Genetic Diseases and Charrow, 2004.  
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Table 3. Autosomal Recessive Ashkenazi Jewish Genetic Diseases 
 
 
Disease 
 
Gene 
AJ 
Carrier 
Frequency 
 
Clinical Features 
Gaucher Disease GBA 1/14 Hepatosplenomegaly, bone disease, fatigue 
Tay-Sachs HEXA 1/25 Neurodegeneration 
Cystic Fibrosis CFTR 1/26 Pulmonary disease, malabsorption 
Familial Dysautonomia IKBKAP 1/30 Sensory and autonomic neuropathy 
Canavan Disease ASPA 1/40 Neurodegeneration 
Spinal Muscular Atrophy SMN1 1/41 Progressive muscle degeneration 
Hyperinsulinemia ABCC8 1/66 Hypoglycemia, FTT, neurologic damage 
 
Glycogen Storage Disease 1A 
 
G6PC 
 
1/71 
Hypoglycemia, hepatomegaly, seizures, 
short stature 
Maple Syrup Urine Disease BCKDHB 1/81 FTT, neurodegeneration 
 
Fanconi Anemia C 
 
FANCC 
 
1/89 
Bone marrow failure, high risk of 
malignancy, dysmorphic features 
 
Niemann-Pick A 
 
SMPD1 
 
1/90 
FTT, hepatosplenomegaly, 
neurodegeneration 
 
Joubert Syndrome 
 
TMEM216 
 
1/92 
Brain malformation, hypotonia, dysmorphic 
features  
Dihydrolipoamide 
Dehydrogenase deficiency 
 
DLD 
 
1/96 
 
FTT, neurodegeneration 
Bloom Syndrome BLM 1/100 High risk of malignancy 
Usher Syndrome III CLRN1 1/107 Progressive hearing and vision loss 
Nemaline Myopathy NEB 1/108 Muscle disease, absent deep tendon reflexes 
Mucolipidosis IV MCOLN1 1/125 Neurodegeneration, eye findings 
 
Usher Syndrome IF 
 
PCDH15 
 
1/141 
Congenital hearing loss, adolescent-onset 
vision loss 
adapted from Victor Centers for Jewish Genetic Diseases, 2012; Charrow, 2004  
 
1.2.3 Genetic Counseling for HBOC 
The goal of cancer genetic counseling is to help “empower the patient to make informed 
decisions regarding screening, prevention and genetic testing by providing him or her with the 
necessary genetic, medical and psychosocial information” (Berliner et al., 2007; Lerman et al., 
1995, 1997; Bernhardt et al., 2000; Lobb et al., 2001; Meiser et al., 2002; Pasacreta, 2003). 
Genetic counseling for HBOC typically consists of both pre- and post-test counseling and begins 
with family history interpretation, cancer risk assessment and psychosocial assessment.  
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If the individual is an appropriate candidate for BRCA1/2 testing, informed consent 
should be obtained (ASCO, 2003). At a minimum, informed consent should include patient 
education of cancer genetics, discussion of medical management guidelines, discussion of the 
genetic testing process, benefits and limitations of genetic testing, discussion of possible 
psychosocial issues associated with genetic testing and identifying relevant resources and 
support in the community (Berliner et al., 2007; Stopfer, 2000).  
           1.2.3.1 Family History Interpretation and Cancer Risk Assessment 
Cancer genetic risk assessment is the process of identifying individuals at an increased risk to 
develop cancer due to hereditary components. A complete risk assessment for HBOC involves 
analysis of the family pedigree, discussion of an individuals’ personal medical history and 
relevant exposures and appropriate use of risk models.  
The family pedigree is the most important aspect to assessing the probability of a 
hereditary component to cancer. Berliner et al., 2007, states that there are several indicators for 
HBOC in a family, including: 
• Pre-menopausal breast cancer 
• Ovarian cancer 
• Bilateral breast cancer, or breast and ovarian cancer in the same individual 
• Male breast cancer 
• Two or more individuals in the family with breast and/or ovarian cancer 
• AJ ancestry 
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There are some instances when the family pedigree is not helpful in assessing risk for 
HBOC. These complications include: limited family history information; small sized families; 
early deaths in the family (unrelated to cancer diagnosis); predominantly male relatives in the 
family; and adoption (Trepanier et al., 2004; ACOG, 2009; Weitzel et al., 2007). 
 There are several different risk calculation models available to assess likelihood of 
identifying a BRCA1/2 mutation in the patient or family. Two such risk models used in clinical 
practice include the Myriad Prevalence Tables (myriadtests.com/provider/brca-mutation-
prevalence.htm) and BRCAPRO (Parmigiani et al., 1998). Myriad Genetics Laboratories, a 
molecular diagnostic company, publishes mutation prevalence tables using data gained from 
clinical testing services. Myriad tables estimate BRCA1/2 mutation probability based on Myriad 
prevalence rates, the individual’s cancer history, family history and AJ ethnicity. BRCAPRO 
uses a Bayesian analysis of conditional probabilities to estimate the likelihood of a BRCA1/2 
mutation based on the individual’s cancer history, family cancer history and AJ ethnicity.  
The combined information from a cancer risk assessment calculation tool provides an 
estimate for an individual’s probability to carry a BRCA1/2 mutation. An estimated probability of 
10% or greater to have a BRCA1/2 mutation is often used to determine appropriateness of HBOC 
genetic testing (ASCO, 2003). Cancer genetic risk assessment also helps determine appropriate 
candidates for genetic testing (Berliner et al., 2007).  
 
           1.2.3.2 Differential Diagnosis 
While HBOC accounts for the majority of hereditary breast cancers and ovarian cancers, there 
are additional, more rare, hereditary cancer predispositions to breast and ovarian cancer (Claus et 
al., 1996; ACOG, 2009; Thull, 2004). Similar to HBOC, these other hereditary cancer 
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syndromes are associated with early-onset cancers, high penetrance and follow an autosomal 
dominant inheritance pattern (Trepanier et al., 2004). See Appendix A for a brief overview of the 
other hereditary predispositions to breast and ovarian cancer.   
           1.2.3.3 Medical Management Options 
While the cancer risks for individuals with a BRCA1/2 mutation are significantly increased over 
those of the general population, there are medical management options available for risk 
reduction and prevention. The options include increased screening/surveillance, 
chemoprevention and risk-reducing surgeries. The National Comprehensive Cancer Network 
2011 Guidelines are outlined in Table 4 and Table 5 (NCCN, 2011).  
Table 4. Medical Management Options for HBOC-associated Breast Cancer 
 
Increased Surveillance Chemoprevention Prophylactic surgery 
 
Monthly breast-self exams 
beginning between age 18 
to 25 years 
 
 
Medications (Tamoxifen/ 
Arimidex) can reduce 
breast cancer risk by 50% 
when taken for 5 years 
 
 
Preventative mastectomy 
can reduce breast cancer 
risk by 90% 
 
 
Annual or semiannual 
clinical breast exams 
beginning between age 25 
to 35 years 
 
 
Preventative removal of the 
ovaries before menopause 
can reduce breast cancer 
risk by 50% 
 
 
Annual mammogram 
beginning between age 25-
35 years 
 
 
Annual breast MRI 
 
adapted from National Comprehensive Cancer Network, 2011  
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Table 5. Medical Management Options for HBOC-associated Ovarian Cancer 
 
Increased Surveillance Chemoprevention Prophylactic surgery 
 
Annual or semiannual 
transvaginal ultrasound 
 
 
Oral Contraceptives can 
reduce ovarian cancer risk 
by 60% when taken for ≥5 
years 
 
Preventative removal of the 
ovaries can reduce ovarian 
cancer risk by as much as 
96% 
 
 
CA-125 blood test 
adapted from National Comprehensive Cancer Network, 2011 
1.2.4 Genetic Testing for HBOC 
Molecular genetic testing for HBOC has been utilized for over a decade, first becoming 
clinically available in October 1996. Diagnosis of symptomatic individuals is the main clinical 
use of molecular genetic testing for HBOC, although predisposition testing for at-risk relatives is 
also utilized (Petrucelli et al., 2010). 
1.2.4.1 Recommendations and Guidelines for Genetic Testing  
The American Society of Clinical Oncology (ASCO, 2003) outlines basic recommendations for 
genetic testing for cancer susceptibility. The recommendations state that genetic testing should 
be offered when there is:  
• Personal or family history features suggesting a genetic cancer susceptibility 
• The genetic test can be adequately interpreted  
• The results will aid in the diagnosis or influence the medical management of the 
patient or family members at hereditary risk of cancer  
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Testing criteria specific to HBOC are published by the National Comprehensive Cancer 
Network (NCCN, 2011). The testing criteria include:  
• Individual from a family with a known BRCA1/2 mutation 
• Personal history of breast cancer (IDC or DCIS) AND 1 or more of the following: 
o Diagnosed ≤ 45 years 
o Diagnosed ≤ 50 years with ≥1 close relative with breast cancer aged ≤ 50 
AND/OR ≥1 close blood relative with ovarian cancer at any age 
o Two breast primaries when 1st diagnosis occurred ≤50 years 
o Diagnosed < 60 years with a triple negative breast cancer  
o Diagnosed < 50 years with a limited family history 
o Diagnosed at any age with ≥ 2 close blood relatives with breast cancer 
AND/OR ovarian cancer at any age 
o Male relative with breast cancer 
o Personal history of ovarian cancer 
o Ashkenazi Jewish or other high-risk background 
• Personal history of ovarian cancer 
• Personal history of male breast cancer 
• Personal history of breast and/or ovarian cancer at any age with ≥ 2 close blood 
relatives with pancreatic cancer at any age 
• Personal history of pancreatic cancer at any age with ≥ 2 close blood relatives 
with breast and/or ovarian and/or pancreatic cancer at any age 
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• Family history only 
o 1st- or 2nd- degree relative meeting any of the above criteria 
o 3rd- degree relative with ≥ 2 close blood relatives with breast AND/OR 
ovarian cancer (≥1 close blood relative with breast cancer aged ≤ 50 years)       
           1.2.4.2 Genetic Testing Methodologies 
There are several clinical methods available for molecular genetic testing of the BRCA genes, 
including sequence analysis, targeted mutation analysis and deletion/duplication analysis. 
Testing is preformed using DNA obtained from a sample of peripheral blood or an oral sample 
obtained by a buccal rinse and results are usually available within two weeks. The majority of 
genetic testing for the BRCA genes is performed at Myriad Genetic Laboratories in Salt Lake 
City, Utah due to patent rights of the sequence analysis. However, there are currently seven 
laboratories in the United States that perform targeted mutation analysis: Myriad Genetic 
Laboratories, Boston University School of Medicine, Fox Chase Cancer Center in Philadelphia, 
PA, New Jersey Medical School, University of California Los Angeles, University of California 
San Francisco, University of Chicago and University of North Carolina Hospitals. 
Targeted mutation analysis looks for the three HBOC-related founder mutations in 
individuals reporting AJ ancestry, detecting an estimated 90% of mutations in this population 
(Petrucelli et al., 2010). Site-specific testing identifies the presence or absence of a known 
familial mutation without having to sequence the entire gene (NCCN, 2011; Petrucelli et al., 
2010). Targeted mutation analysis ranges in cost from $325 to $2,975 depending on the lab 
performing the test and is usually covered by most insurance plans (Deegan et al., 2010; 
Myriad2, 2010).  
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Comprehensive analysis, termed “BRACAnalysis” by Myriad Genetic Laboratories, has a 
detection rate of 85% and consists of full sequencing, as well as detection of five common large 
genomic rearrangements in BRCA1 (Petrucelli et al., 2010; Frank et al., 1998; Walsh et al., 
2006; Unger et al., 2000). ). The total cost is $3,340 and 90% of health insurance plans will 
cover the cost at 90% or better (Myriad2, 2010). BRACAnalysis Large Rearrangement Test, 
termed “BART” by Myriad Genetic Laboratories, is complementary to comprehensive analysis 
and looks for additional large genomic rearrangements in BRCA1 and BRCA2 if no mutations are 
detected with standard comprehensive analysis. BART examines all coding exons and promoters 
of BRCA1 and BRCA2 for deletions and duplications, picking up an additional 3-4% of 
mutations (Petrucelli et al., 2010; Myriad1, 2010). For patients meeting specific criteria 
established by Myriad Genetic Laboratories based on both a personal diagnosis of cancer and 
family history, BART is free of charge. There is an additional charge of $700 for individuals that 
do not meet these criteria and to date, many insurers do not cover this additional testing. 
           1.2.4.3 Genetic Testing Strategies and Result Interpretation 
To ensure adequate interpretation of test results, it is standard of practice that genetic testing for 
BRCA1 and BRCA2 be initiated in a member of the family with a history of breast and/or ovarian 
cancer whenever possible because: a) It will clarify the risk of other HBOC-associated cancers 
for the affected family member; b) If no mutation is identified, testing unaffected family 
members is not necessary or useful (thus conserving healthcare resources); and c) If a mutation is 
identified, it makes test results in unaffected family members more informative and allows for 
site-specific testing of family members.   
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For individuals of AJ ancestry, it is recommended that initial testing consist of targeted 
mutation analysis for the three specific founder mutations. If no mutations are detected with the 
three-site panel and the individual meets NCCN Testing Criteria for HBOC despite their AJ 
ancestry, reflex to comprehensive analysis is performed due to the possibility that an AJ 
individual could have a BRCA mutation that is not one of the three founder mutations (NCCN, 
2011; Petrucelli et al., 2010). It is suggested that other individuals within a family of AJ decent 
who wish to undergo genetic testing include analysis for all three common AJ founder mutations 
rather than just being tested for the mutation previously identified in the family because of 
reports of coexistence of two founder mutations in some AJ families due to the frequency of 
these mutations (Lavie et al., 2011; NCCN, 2011; Petrucelli et al., 2010). 
There are four possible test results from analysis of the BRCA genes. A true positive test 
result means that an individual is a carrier of a mutation in BRCA1/2, which increases the risk for 
HBOC-associated cancers. A true negative result indicates that an individual is not a carrier of a 
BRCA1/2 mutation previously identified in the family. A “no mutation detected” result describes 
an individual who was not found to be a carrier of a BRCA1/2 mutation and the carrier status of 
other family members may either be positive, negative or unknown. Lastly, a Variant of 
Uncertain Significance (VUS), result offers information about an alteration in BRCA1/2 for 
which the risk for HBOC-associated cancers with the particular alteration is unknown. 
 
           1.2.4.4 Understanding the Benefits and Limitations of Genetic Testing 
An integral component to pre-test counseling for HBOC is a discussion of the benefits and 
limitations of testing. The main benefit is a personalized risk assessment. Information about 
mutation status can help in making informed choices regarding medical management strategies. 
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Another benefit of genetic testing for HBOC includes an accurate risk assessment for other 
members of the family; identifying a BRCA mutation in one family member enables other 
relatives to determine whether or not they share the same cancer predisposition. 
Genetic testing for HBOC is not perfect and it is necessary that the limitations be 
presented to the patient as well as the benefits. The detection rate for BRCA testing is 85 to 90%, 
depending on the population and test method; however, not all mutations can be detected using 
current testing technologies (Walsh et al., 2006). For this reason, a negative test result is most 
informative when there is a known mutation in the family. It is possible that the genetic test will 
detect a VUS and the contribution of the variant to cancer risks is unknown. In the event that a 
VUS is detected, medical management decisions and further testing options are based on 
personal and family history. In addition, the BRCA genes are not the only genes that contribute to 
hereditary breast cancer and hereditary ovarian cancer (Berliner et al., 2007).  
The theoretical concern of genetic discrimination is often discussed during cancer genetic 
counseling sessions. A long-time barrier of genetic testing has been fear of insurance 
discrimination based on genetic test results. In 1996, the government enacted the Health 
Insurance Portability and Accountability Act (HIPAA), which protects patient’s privacy and 
provides some protection against genetic discrimination with regard to health insurance for 
individuals with group policies (Fleisher et al., 2001; Trepanier et al., 2004). In 2008, the 
government enacted the Genetic Information Nondiscrimination Act (GINA), which protects 
patients from potential discrimination from health insurances and employers based on genetic 
information (Petrucelli et al., 2010).    
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1.2.5 Psychosocial Issues Related to HBOC 
There is a wide array of psychosocial issues that can arise before, during and after genetic 
counseling and/or testing for HBOC. When individuals receive the results of their genetic test 
and are informed of their mutation status, they will no longer be at an arbitrary “increased risk” 
status; they will be faced with the knowledge of actual cancer risks (whether increased or 
decreased, based on testing results). An individual’s personal cancer history, as well as stage of 
life, can have a large impact on the reaction to their test results as well as their thoughts 
concerning medical management strategies.   
For individuals who have had an HBOC-associated cancer, a positive test result can bring 
mixed emotions. For some, a positive test result can bring a sense of relief because it provides an 
“explanation” for the cancer diagnosis. For others, a positive result may bring a sense of 
anxiousness, sadness, or fear because the individual is now faced with additional cancer risks. 
Some individuals can experience both relief and anxiousness after receiving a positive result 
(Douglas et al., 2009).  
For an individual that has never had cancer, learning that they are positive for a BRCA 
mutation places that otherwise healthy individual at substantially increased risk for potentially 
life-threatening illnesses. “Previvor” is a term coined in 2000 by individuals on the Facing Our 
Risk Of Cancer Empowered (FORCE) community blog describing “unaffected carriers” of 
BRCA mutations as survivors of a predisposition to cancer. Cancer previvors face unique 
challenges and stress over the difficult decisions that come with the many medical management 
options for those with a BRCA mutation (FORCE, 2012). 
Just like a positive result, learning that no mutation in BRCA was detected can bring 
mixed emotions. For most, a negative test result is reassuring and brings relief because the 
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individual is not known to have substantially elevated risks for the development of HBOC-
related cancers (Lerman et al., 1998). For some, a negative result can be associated with 
“survivor guilt”, especially if a mutation has previously been identified in the family and was 
inherited by siblings but not themselves (Wagner et al., 2000; Tibben et al., 1992; Huggins et al., 
1992). 
An individual’s stage of life can also have a large impact on their thoughts concerning 
medical management strategies and influence their decision making process with regards to 
surveillance versus prophylactic surgeries (Wagner et al., 2000). 
Regardless of personal cancer history or stage of life, many individuals who test positive 
for a BRCA mutation contend with possible guilt and worry over passing a mutation to children, 
as well as having concern for creating guilt for a parent or grandparent from whom the mutation 
was inherited. Individuals may feel a strong psychosocial burden over having to inform the 
family of a mutation and being the “bearer of bad news” (Lubinsky, 1994). Individuals who learn 
they carry a BRCA gene mutation may experience depression. Although most BRCA mutation 
carriers can cope with this information over time, some individuals experience prolonged periods 
of depression or are unable to adjust to this genetic diagnosis and require referral for more 
involved psychosocial support. 
           1.2.5.1 Patient Support and Resources 
There are many different sources of support for individuals and families with HBOC. Numerous 
websites, outreach programs and support groups are dedicated to helping individuals wanting 
support and information about HBOC.  
FORCE is a nonprofit organization dedicated to providing information, resources and 
support to individuals and families facing hereditary breast and/or ovarian cancer 
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(www.facingourrisk.org). Bright Pink is a nonprofit organization dedicated to helping young 
women who are at high risk for breast and ovarian cancer (brightpink.org). Bright Pink aims to 
provide education to empower women to take control of their health and medical management 
strategies. Sharsheret, meaning “chain” in Hebrew, is a nonprofit organization dedicated to 
helping Jewish young women and their families who face breast cancer (www.sharsheret.org). 
Sharsheret helps young women with breast cancer or a BRCA mutation to make “culturally-
relevant individualized connections” to peers, support groups, health professionals and other 
resources. FORCE, Bright Pink and Sharsheret are just a few of the numerous organizations that 
provide excellent resources for the HBOC-community. 
1.3 PREVIOUS RESEARCH OF POPULATION-SPECIFIC GENETIC TESTING AND 
COUNSELING  
It is important for genetic counselors to be aware of a patient’s ethnic, racial and religious 
background because it can provide important information about how a patient will interpret and 
utilize genetic information, as well as allow for multi-culturally sensitive and specific genetic 
counseling (Berliner et al., 2007; Mitchell, 1998; Trepanier et al., 2004). When counseling 
individuals of AJ ancestry, it may be important to be aware of the ethical understandings of 
genetic testing from the Jewish code of ethics, as well as to be aware of previous research 
pertaining to the beliefs of AJ individuals in regards to genetic testing and counseling for HBOC. 
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            1.3.1 Ethical Implications of Genetic Testing in the AJ Population  
The approach to health care and decision-making in western culture is driven by autonomy, 
meaning that the individual has the right to make their own decisions concerning health care 
(Callahan, 2003). Under Jewish law, health care and decision-making is driven by obligation and 
responsibility to protect one’s health, not an individuals “right” to make their own decisions 
(Steinberg, 2003). Under Jewish law (Deuteronomy 4:9; 4:15), having a diagnosis of cancer and 
not seeking treatment or undergoing routine screenings recommended by a physician would be 
defiant because it would be going against the law of “guard[ing] [one’s] health” (Mor et al., 
2008; Fisch, 1984). Genetic testing for HBOC does not specifically fall under this tenant of 
Jewish law because having a mutation in a BRCA gene implies a predisposition to cancer, not a 
diagnosis of cancer. However, rabbinical consensus is consistent with western medical 
professionals’ recommendations: in most cases where there appears to be a hereditary 
predisposition for breast and/or ovarian cancer, there is an obligation to test (Mor et al., 2008; 
Steinberg 2003).  
While the decision, or “obligation”, to test is supported by Jewish law in the Orthodox 
community, the decision to undergo risk-reducing surgeries is not as straight forward and the 
idea of sharing genetic information, even with family members, is sometimes considered a 
breach of Jewish law (Mor et al., 2008). Sharing information with Orthodox family members 
about a BRCA mutation could impact marriage prospects for others in the family, bring fear of 
social discrimination and label the family as “defective” (Rosner, 1998; Mor et al., 2008). Unless 
a genetic counselor has prior knowledge of possible social implications for Orthodox Jewish  
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women, genetic counseling and testing for HBOC in this population may not be effective. 
Reports in the literature are limited in regards to the ethical implications of BRCA testing for 
individuals with Reform Judaism or Conservative Judaism beliefs.  
           1.3.2 Previous Research of CGS for HBOC in the AJ Population  
Genetic counselors having a prior awareness of possible motivations for and unique barriers to 
cancer genetic counseling and testing in the AJ population may be a helpful aide for 
implementing more effective counseling strategies. There have been several studies conducted 
that focus on the beliefs of AJ individuals regarding genetic testing for HBOC; however, studies 
that focus specifically on genetic counseling for HBOC in the AJ population are limited. 
Phillips et al., 2000, conducted a multicenter study of 134 Canadian women with AJ 
ancestry using questionnaires that examined the factors that influenced their decision to undergo 
genetic testing for BRCA1/2. This study found that the main motivating factors for testing 
included [their] desire to contribute to research, implications for family members and “the need 
to know”. Study participants felt that the main discouraging factors to testing included fear of 
insurance discrimination, potential impact on marriage prospects and concern about the negative 
focus on the Jewish community.  
Lehmann et al., 2002, conducted a population-based study of 200 AJ women through 
telephone surveys that examined their attitudes towards genetic discrimination and BRCA1/2 
testing, as well as perceived advantages and disadvantages of BRCA1/2 genetic testing. Their 
study revealed that there is significant variation among AJ women’s interest in BRCA1/2 testing, 
however, the majority of participants were not concerned about group discrimination based on 
BRCA1/2 test results. In fact, 95% of the study population felt that research focused on Jews was 
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either neutral or good. The main perceived advantages of BRCA1/2 genetic testing included 
obtaining information about [their] children’s risk of disease and valuing information for its own 
sake. The main perceived disadvantages of BRCA1/2 genetic testing included fear of insurance 
discrimination and increased anxiety from knowing mutation carrier status. 
Kelly et al., 2004, conducted a study using repeated-measures surveys that examined 
cancer genetics knowledge and beliefs before and after traditional genetic counseling and their 
relationship to receipt of results for BRCA1/2 mutations in 120 highly educated AJ individuals. 
The study population included individuals who had a personal or family history suggestive of a 
BRCA1/2 mutation. Their study revealed that genetic counseling is helpful in improving overall 
knowledge of cancer genetics even for highly educated AJ individuals, although continued 
communication regarding the implications of genetic risk may require additional educational 
materials and may need to be conducted over time.  
Bowen et al., 2003, conducted a study of 221 AJ women from Seattle, WA that explored 
the connections between Jewish identity (cultural identification and religious practice) and 
interest in screening behaviors (mammography, breast self-exam, genetic testing). This study 
was part of a larger study that examined the efficacy of two counseling methods for AJ women 
(Bowen et al., 2006). Study participants completed surveys and multiple regressions were 
examined. Findings revealed that cultural identity positively predicted interest in testing, whereas 
religious identity was inversely related. Religious identity was a significant predictor of intention 
to adhere to mammography recommendations. Findings show that culture and religion, although 
correlated, may have different associations with health attitudes. 
Bowen et al., 2006, conducted a study of 221 AJ women with average or moderately 
increased risk of breast cancer to test the efficacy of two counseling methods: individual genetic 
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counseling and psychosocial group counseling. Individual genetic counseling emphasized 
information and explaining hereditary cancer risk. Psychosocial group counseling emphasized 
discussion of emotions, distress, and coping with cancer risks. Researchers reported that many 
AJ women initially overestimated their risk but that genetic counseling lowered risk perceptions. 
The study revealed that providing AJ women who are of average or moderately increased breast 
cancer risk with either traditional genetic counseling or psychosocial group counseling reduced 
worry about cancer, lowered inflated perceptions of breast cancer risk and decreased interest in 
having genetic testing. 
           1.3.3 Previous Research of Population-specific Genetic Counseling for HBOC  
Several research studies have shown lower rates of cancer genetic counseling and BRCA1/2 
testing in individuals belonging to minority populations, specifically the African American (AA) 
population, than those in the general population (Forman et al., 2009). With the knowledge that 
diligent screening and early detection of cancer increases the chances for a better health 
outcome, this health disparity encouraged researchers to understand the knowledge, attitudes and 
emotional barriers to cancer genetic counseling and testing in the AA population specifically 
(Lerman et al., 1999; Williams, 1999; Kendall et al., 2007).   
Researchers discovered perceived barriers for obtaining CGS in the AA population, 
including: concern for ethical implications and discrimination, differing levels of genetic 
knowledge, resistance to risk-reducing strategies and the belief that [their] health was “in God’s 
hands” (Thompson et al., 2003; Singer et al., 2004; Kendall et al., 2007). While concerns of  
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blame and guilt are not unique to the AA population, these barriers have frequently been reported 
in regards to genetic testing for hereditary cancer predispositions (Thompson et al., 2003; 
Kendall et al., 2007). 
Lerman et al., 1999, conducted a randomized trial of two hundred twenty-eight 
Caucasian women and 70 African American (AA) women with a family history of breast or 
ovarian cancer to investigate racial differences in response to two alternate pretest education 
strategies for BRCA genetic testing: a standard education model and an education plus 
counseling model. The standard education model only provided information about genetic testing 
to participants, and the education plus counseling model incorporated the information with 
additional discussion relating to psychosocial issues in genetic testing. This study found that the 
effects of the interventions on testing intentions in AA women differed significantly from 
Caucasian women. The education plus counseling model in the AA women led to greater 
increases in intentions to be tested than the education only model. In Caucasian women, there 
was no notable difference on outcome despite different interventions. These findings are 
indicative that genetic counselors need to be aware of the unique aspects to cancer counseling in 
the AA population, as well as tailoring genetic counseling for individuals who report AA 
ancestry.  
 While the information that was gained from these studies supports the idea of population-
specific genetic counseling, there has been little research conducted specifically on AJ 
individual’s beliefs regarding CGS for HBOC (Lehmann et al., 2002). In order to best serve the 
AJ community, genetic counselors need to learn from the research done in the AA population 
and embrace the idea of AJ population-specific genetic counseling. 
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2.0  EXPERIMENTAL DESIGN AND METHODS 
This pilot study, which culminated in an information session, was conducted on December 11, 
2011 from 10:00-11:30am at Rodef Shalom Congregation in Pittsburgh, Pennsylvania. The study 
was a collaboration of efforts between the University of Pittsburgh and the Cancer Genetics 
Program of the West Penn Allegheny Health System, which provides genetic counseling and 
testing services, as well as outreach genetic counseling services in Western Pennsylvania.  
The study facilitated analysis of the current awareness of, perceived beliefs regarding and 
preferred methods of communicating cancer genetics information in the AJ population. Surveys 
completed by the study participants before and after the information session helped to assess 
knowledge gained and a difference in opinions regarding CGS. Approval was obtained from the 
Institutional Review Boards at the University of Pittsburgh and Allegheny General Hospital of 
the West Penn Allegheny Health System (Appendix B).  
2.1 PROTOCOL 
           2.1.1 Advertisement and Recruitment 
The information session was advertised as a program about Jewish genetic diseases, specifically 
HBOC. Advertisement for the information session began two months prior to the event and 
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continued until the day before the event. The various forms of advertisement can be found in 
Appendix C and consisted of: an advertisement in the Rodef Shalom Bulletin; an article in the 
Jewish Chronicle; flyers that were distributed at Rodef Shalom, Allegheny General Hospital and 
a Jewish Genetic Disease Screening event at Hillel Jewish University Center of Pittsburgh in 
November; and by word of mouth. 
Two genetic counselors greeted all attendees before the information session and briefly 
explained the study and invited them to participate. If the individual expressed interest in the 
study, they were given a packet of information containing the pre- and post-information session 
surveys (Appendices F and H), a copy of the PowerPoint presentation about HBOC given during 
the session (Appendix G), several educational brochures about HBOC (described in section 
1.2.5.1), a handout discussing the Jewish perspective of taking care of the body (Appendix D) 
and the program agenda (Appendix E). The individuals who declined to participate in the study 
were still provided with the educational brochures, program agenda and a copy of the 
PowerPoint presentation. In accordance with Institutional Review Board (IRB) regulations for 
pilot studies, a maximum of 25 individuals could participate in the research study. However, no 
attendees were turned away from participating in the event.   
           2.1.2 Surveys 
Participants were given a pre-information session and post-information session survey to 
complete. The pre-session survey was to be completed before the start of the information session 
and included questions pertaining to demographics and basic genetic knowledge including 
inherited cancer risks, genetic counseling and genetic testing for HBOC. The post-session survey 
was to be completed following the information session and asked the same questions as the pre-
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session survey, allowing researchers to identify changes in genetic knowledge, as well as 
differences in perceptions about cancer genetics and genetic counseling services from before the 
information session. Participants were given the option to stay after the session and complete the 
post-session survey at Rodef Shalom, or return the post-session survey using a provided pre-paid 
and pre-addressed envelope.  
           2.1.3 Participants 
The study participants were AJ individuals with an interest in HBOC. The participants were 
recruited on a voluntary basis from the Jewish community of Pittsburgh, Pennsylvania, with the 
majority of participants learning of the event through the advertisement in the Jewish Chronicle.  
A large proportion were also members of Rodef Shalom Congregation. Participants understood 
that they would not be compensated for the study. The only incentive for the participants was 
gaining knowledge of hereditary cancer information and the services available to assess cancer 
risks and medical management options.  
Inclusion criteria included AJ ancestry by birth (as reported by the participant) and 
participants had to be over age 18 because genetic testing for inherited susceptibilities to HBOC 
in children is not indicated. Gender and race were not included as inclusion or exclusion criteria. 
Exclusion criteria included mentally incompetent individuals or members of any other legally 
restricted group. 
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           2.1.4 Information Session  
The session, led by genetic counseling intern Rachel Pearlman, consisted of guest speakers 
telling their personal stories, a PowerPoint presentation on HBOC and concluded with a panel 
Question and Answer session.  
The session opened with an introduction from Rabbi Amy Hertz, followed by guest 
speakers Mr. Jay Rogal and Mrs. Barbara Rogal and Mrs. Kathy Pattak. Rabbi Hertz briefly 
spoke about the Jewish perspective “Shmirat HaGuf”, which is Hebrew for “taking care of the 
body”. Mr. and Mrs. Rogal spoke about their personal experience with Gaucher’s Disease, as 
well as their involvement in Jewish Genetic Disease Screening within the Jewish community of 
Pittsburgh. Mrs. Kathy Pattak, an AJ individual who carries a BRCA2 mutation, spoke about her 
personal experience with genetic testing, counseling and medical management decisions.  
The information that was included in the PowerPoint presentation on HBOC consisted of 
an overview of genetics, inherited cancer syndromes, risk assessment, available medical 
management options, available genetic testing, benefits and limitations of testing and access to 
these services (Appendix G).  
The program concluded with a panel Question and Answer session consisting of two 
genetic counselors, a genetic counseling intern and Rabbi Hertz. 
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2.2 DATA ANALYSIS 
After the information session was complete and the surveys were returned, the collected data 
from the pre- and post-session surveys were analyzed using a qualitative descriptive method. 
Descriptive statistics were produced for selected characteristics of the sample; means, ranges and 
frequencies, were reported where appropriate. Likert scales were used to analyze information and 
themes were identified.  
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3.0  RESULTS 
3.1 RESPONSE RATE 
Forty-five individuals attended the event. In accordance with the IRB, 25 individuals were 
consented to participate in the study. Of the 25 individuals who agreed to participate, 16 
individuals completed and returned the pre-session survey (64%). Of the 16 individuals who 
returned the pre-session survey, 8 individuals also completed and returned the post-session 
survey (50%). Therefore, 32% (8/25) of individuals who originally agreed to participate in the 
research study completed both the pre- and post-information session surveys.  
3.2 DEMOGRAPHICS 
Data from 16 individuals that attended the information session and completed the questionnaires 
were used in this study. Table 6 illustrates the characteristics of the participants by several 
categories including: gender, age, marital status, family status, education level and religious 
affiliation.  
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Table 6. Characteristics of Participants (Demographics) 
 
Variable (n=16) 
 
Category 
Number of 
Responses  
 
(%) 
 
Gender 
 
Female 
 
11 
 
68.75 
 Male 5 31.25 
 
Age 
 
18-25 
 
1 
 
6.25 
 26-30 0 0 
 31-40 2 12.5 
 41-50 0 0 
 51-60 6 37.5 
 61-70 5 31.25 
 70+ 2 12.5 
 
Marital Status 
 
Single 
 
1 
 
6.25 
 Married 11 68.75 
 Divorced 1 6.25 
 Widowed 1 6.25 
 In a relationship 2 12.5 
 
Family Status 
 
Children 
 
13 
 
81.25 
 No children 3 18.75 
 
Education level 
 
Some high school 
 
0 
 
0 
 High school graduate 1 6.25 
 Some college 1 6.25 
 College graduate 6 37.5 
 Graduate/professional school 8 50 
 
Religious status 
 
Reform 
 
10 
 
62.5 
 Conservative 3 18.75 
 Orthodox 2 12.5 
 Jewish 1 6.25 
 Other 0 0 
 None 0 0 
      
All individuals were of AJ ancestry. Twice as many females (68.75%) participated in the 
study than males (31.75%). The ages of study participants were grouped and the groups ranged 
from 18 years to 70+ years. The majority of the participants, 37.5%, were between 51 and 60 
years of age. The majority of participants were married (68.75%), had children (81.25%) and had 
a post-High School education. 50% had a graduate/professional degree and 37.5% had a college 
degree. The majority of participants identified with Reform Judaism (62.5%). 
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Table 7 illustrates cancer-specific characteristics of the study participants including: 
personal diagnosis of cancer, family history of cancer diagnosis (first-degree or second-degree), 
type of cancer (breast and/or ovary cancer or other type of cancer) and age range of cancer 
diagnosis (>50 or <50). 
Table 7. Characteristics of Participants (Cancer-specific) 
 
Variable (n=16) 
 
Category 
Number of 
Responses 
 
(%) 
 
Personal cancer diagnosis 
 
Br/Ov cancer > 50 
 
2 
 
12.5 
 Br/Ov cancer < 50 0 0 
 Other types of cancer 1 6.25 
 No cancer 13 81.25 
First-degree relative with 
cancer diagnosis 
 
Br/Ov cancer > 50 
 
2 
 
12.5 
 Br/Ov cancer < 50 5 31.25 
 Other types of cancer 3 18.75 
Second-degree relative 
with cancer diagnosis 
 
Br/Ov cancer > 50 
 
2 
 
12.5 
 Br/Ov cancer < 50 3 18.75 
 Other types of cancer 1 6.25 
 
The majority of individuals that participated (81.25%) had never been diagnosed with 
cancer. There were no participants that were diagnosed with breast or ovarian cancer before age 
50. 31.25% of participants reported having a first-degree relative diagnosed with breast and/or 
ovarian cancer under the age of 50 years and 18.75% of participants reported having a second-
degree relative diagnosed with breast and/or ovarian cancer under the age of 50 years.   
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3.3 AWARENESS OF CGS 
Study participants were asked a variety of questions in the pre-session survey concerning 
awareness of CGS, specifically; genetic counseling, general genetic testing and genetic testing 
for hereditary cancer predispositions. Table 8 shows participant responses of awareness prior to 
attending the information session.  
Table 8. Awareness of CGS 
 
Variable (n=16) 
 
Category 
Number of 
Responses 
 
(%) 
 
Previous knowledge of GC 
 
Yes 
 
14 
 
87.5 
 No 0 0 
 No response 2 12.5 
If yes: 
Reason for previous knowledge of GC 
 
Personal experience 
 
5 
 
35.7 
 Healthcare provider 2 14.3 
 Relative 6 42.85 
 Friend 4 28.6 
 Newspaper/magazine 2 14.3 
 Internet 2 14.3 
 Synagogue 4 28.6 
 Other (work) 1 7.1 
Previously had genetic testing Yes 11 68.75 
 No 5 31.25 
 Unsure 0 0 
Previously had genetic counseling Yes 9 56.25 
 No 7 43.75 
 Unsure 0 0 
Previous knowledge of testing for 
hereditary cancer predisposition 
 
Yes 
 
12 
 
75 
 No 1 6.25 
 No response 3 18.75 
 
The majority of individuals (87.5%) reported that were previously aware of genetic 
counseling and 75% were aware of testing for hereditary cancer predisposition before attending 
the information session. Two individuals who completed the pre-session survey did not respond 
to this question, so they were not included in the analysis. 
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Of the 14 individuals that reported having prior knowledge of genetic counseling, the 
main source was communication with relatives (42.85%). 35.7% of respondents reported having 
a previous personal experience with genetic counseling. Communication with friends and 
information from the synagogue tied with 28.6% for the third most common reason for prior 
knowledge of genetic counseling. 68.75% of respondents previously underwent genetic testing 
and 56.25% of respondents participated in genetic counseling. It should be noted that some 
individuals selected more than one answer for how they learned of genetic counseling.  
3.4 BELIEFS REGARDING CGS 
Study participants were asked to rate a variety of possible motivations for and perceived barriers 
to obtaining CGS for HBOC using a five-level Likert scale. Participants were asked to do the 
same in the post-session survey so that changes due to information gained during the information 
session could be analyzed.  
To analyze motivations for seeking CGS, Table 9 illustrates the participant’s personal 
perceived risk for cancer development based on their personal and family cancer history. 
Analysis of the pre-session surveys revealed that 6 of the 16 participants responded to the 
question inquiring about personal perceived cancer risk, so the individuals who did not respond 
were not included in the analysis of personal perceived cancer risk.  
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Table 9. Perceived Cancer Risk Based on Personal and Family History 
 
Variable (n=16) 
 
Level of Perceived Risk 
 
(%) 
 
Perceived cancer risk 
Low (0-3) Neutral (4-6) High (7-10)  
Pre Post Diff Pre Post Diff Pre Post Diff 
 
Personal cancer diagnosis (br/ov) 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
1 
 
1 
 
0 
 
16.6 
 
No family history 
 
1 
 
1 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
16.6 
First-degree relative with br/ov 
cancer diagnosis 
 
1 
 
1 
 
0 
 
0 
 
0 
 
0 
 
1 
 
1 
 
0 
 
33 
Second-degree relative with br/ov 
cancer diagnosis 
 
1 
 
1 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
16.6 
First-degree relative with cancer 
diagnosis (not br/ov) 
 
0 
 
1 
 
0 
 
1 
 
0 
 
0 
 
0 
 
0 
 
0 
 
16.6 
Second-degree relative with 
cancer diagnosis (not br/ov) 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
0 
 
As would be anticipated, the participants with a personal history of cancer perceived their 
cancer risk as high. The participant with no family history of cancer perceived their risk as low. 
One participant with a 1st-degree relative with breast and/or ovarian cancer perceived their 
cancer risk as high, while another participant with a 1st-degree relative with breast and/or ovarian 
cancer perceived their cancer risk as low. Analysis of the post-session surveys revealed that one 
participant (16.6%) went from feeling that their cancer risk was neutral to feeling that their 
cancer risk was low.  
Participant’s motivations for participating in cancer genetic counseling and testing are 
illustrated in Table 10. It should be noted that 4 of the 16 individuals who completed the pre-
session survey did not respond to the questions inquiring about perceived benefits to CGS, so 
they were not included in the results. Because not all participants completed the post-session 
survey, Table 10 is split into analysis of participants who completed the pre-survey only (n=12) 
(top portion of table) and analysis of participants who completed both the pre- and post-survey 
(n=8) (bottom portion of table).  
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Table 10. Benefits for Seeking CGS for HBOC 
Benefit (n=12) Disagree (1-2) Neutral (3) Agree (4-5) 
Pre Post Diff Pre Post Diff Pre 
 
Post 
 
Diff 
 
Knowledge of increased risk is useful 1 0 3 
Knowledge of mutation status is useful 1 0 3 
Knowledge of risk would influence medical 
management decisions 
1 0 3 
Knowledge of increased risk is useful 0 0 0 0 0 0 8 8 0 
Knowledge of mutation status is useful 0 0 0 1 0 -1 7 8 +1 
Knowledge of risk would influence medical 
management decisions 
0 0 0 2 0 -2 6 8 +2 
 
Analysis of the pre-session surveys revealed that the majority of participants agreed that 
the greatest benefit to undergoing genetic counseling for HBOC was the usefulness of knowing 
increased cancer risk status (91.6%). The majority of participants also felt that knowledge of 
mutation status would be beneficial (83.3%) and knowledge of cancer risk status would influence 
their medical management decisions (75%).  
Analysis of the post-session surveys revealed that one person (12.5%) went from feeling 
neutral to agreeing that knowledge of mutation status would be useful. Two (25%) people went 
from feeling neutral to agreeing that knowledge of cancer risk status would influence their 
medical management decisions. The post-session survey revealed that 100% of the participants 
felt that knowing increased cancer risk status, mutation status and their influences on medical 
management decisions were equally beneficial. 
Questions dedicated to ascertaining perceived barriers to participating in cancer genetic 
counseling and testing were also analyzed and are displayed in Table 11. It should be noted that 
8 of the 16 individuals who completed the pre- survey did not return the post-survey. Because  
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not all participants returned the post-survey, Table 11 is split into analysis of participants who 
completed the pre-survey only (n=16) (top portion of table) and analysis of participants who 
completed both the pre- and post-survey (n=8) (bottom portion of table).  
Table 11. Perceived Barriers to Obtaining CGS for HBOC 
Barrier (n=16) Disagree (1-2) Neutral (3) Agree (4-5) 
Pre Post Diff Pre Post Diff Pre 
 
Post 
 
Diff 
 
Painful/difficult 5 0 1 
Increase anxiety/worry 3 1 2 
Feel guilty if passed to children 3 1 1 
Unable to find a GC in the area 4 0 1 
Fear of insurance discrimination 2 0 2 
Feel ashamed/singled-out in community 3 0 1 
Fear of knowing cancer risk 2 0 4 
Lack of genetic information 2 0 5 
Unsure of family history 2 2 3 
Test result would be beneficial 1 0 4 
Cost 4 1 1 
Painful/difficult 6 6 0 1 0 -1 1 2 +1 
Increase anxiety/worry 2 2 0 1 1 0 4 5 +1 
Feel guilty if passed to children 3 4 +1 2 1 -1 3 3 0 
Unable to find a GC in the area 8 7 -1 0 1 +1 0 0 0 
Fear of insurance discrimination 6 5 -1 1 2 +1 1 1 0 
Feel ashamed/singled-out in community 8 7 -1 0 0 0 0 0 0 
Fear of knowing cancer risk 1 1 0 1 2 +1 6 5 -1 
Lack of genetic information 1 3 +2 1 0 -1 6 5 -1 
Unsure of family history 1 3 +2 2 0 -2 5 5 0 
Test result would be beneficial 0 0 0 0 0 0 8 8 0 
Cost 6 4 -2 1 1 0 1 2 +1 
 
Analysis of the pre-session survey revealed that the majority of participants agreed that 
the greatest barrier to seeking CGS was lack of genetic information (68.75%). Fear of knowing 
cancer risk (62.5%) and not knowing family history (50%) were also among the greatest 
perceived barriers. The majority of participants disagreed that fear of pain or difficulties 
obtaining testing were barriers (68.75%). The majority of participants disagreed that cost 
(62.5%), inability to find a genetic counselor (75%), fear of insurance discrimination (50%) and 
fear of feeling ashamed or singled-out in the Jewish community (68.75%) were barriers.  
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Analysis of the post-session survey revealed that the majority of participants agreed that 
the greatest barriers to obtaining CGS for HBOC included lack of genetic information (62.5%), 
an increase in anxiety or worry (62.5%), fear of knowing cancer risk (62.5%) and uncertainty of 
family history (62.5%). In addition, analysis of the post-session survey revealed that the majority 
of participants disagreed that the inability to find a genetic counselor (100%), fear of insurance 
discrimination (87.5%) and fear of feeling ashamed or singled-out in the Jewish community 
(100%) were barriers to obtaining CGS for HBOC. 
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3.5 PREFERRED COMMUNICATION STRATEGIES 
As illustrated in Table 12, study participants were asked a variety of questions in the pre-session 
survey concerning preferred methods of communication in regards to cancer risk and family 
history, as well as main sources of support (other than family) and physician awareness of AJ 
ancestry.  
Table 12. Communication Strategies 
 
Variable (n=16) 
 
Category 
Number of 
Responses 
 
(%) 
 
Best method for communicating risk 
 
Healthcare provider 
 
12 
 
75 
 Relative 6 37.5 
 Friend 4 25 
 Newspaper 2 12.5 
 Internet 4 25 
 Synagogue 5 31.25 
 Other 0 0 
 
Main sources of support (other than family) 
 
Healthcare provider 
 
2 
 
12.5 
 Religious organization 6 37.5 
 Support group 4 25 
 Colleagues 1 6.25 
 Friendships 8 50 
 
Physician awareness of AJ ancestry 
 
Yes 
 
3 
 
18.75 
 No 9 56.25 
 Unsure 1 6.25 
 No response 3 18.75 
 
The majority of participants (75%) felt that their healthcare provider was the best method 
for communicating information about cancer risk and family history. Other preferred methods of 
communication included relatives (37.5%) and the synagogue (31.25%). Other than family, 
participants reported that their religious organization (37.5%) was their main source of support in 
terms of communicating cancer risk and family history. 56.25% of individuals reported that their 
health care providers were unaware of their AJ ancestry. 
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3.6 CHANGE IN KNOWLEDGE 
The participants were asked a series of knowledge-based questions, found in the pre- and post-
session surveys. The majority of questions were multiple-choice with a few true/false questions. 
The answers to all questions were provided during the information session. Table 13 illustrates 
the comparison of the participant’s answers from the pre- and post-surveys (n=8), as well as an 
analysis of gain in knowledge.   
Table 13. Assessment of Knowledge 
Question  Correct (n=8) 
 
Pre Post Difference 
1. The majority of all cancer is hereditary (T/F) 7 8 +1 
2. How common is breast cancer in the general population? 5 6 +1 
3. How common is hereditary breast cancer in the general population? 3 6 +3 
4. How common is hereditary breast cancer in the AJ population? 5 8 +3 
5. Cancer is only passed through your mother (T/F) 7 8 +1 
6. Having a cancer gene means you will definitely develop cancer (T/F)  8 8 0 
7. Inheriting a mutation in a cancer gene increases the risk that you will 
develop specific types of cancer (T/F) 
7 8 +1 
8. How many genes must someone inherit to have HBOC? 5 7 +2 
9. How can you tell if someone carries a gene that increases the risk for 
HBOC? 
6 8 +2 
10. If a person has genetic testing and no mutation is found in a cancer 
gene, that person will never develop cancer (T/F) 
8 8 0 
11. A mutation in a breast cancer gene also contributes to a higher risk 
of ovarian cancer (T/F) 
6 8 +2 
12. Our genetic code (DNA) consists of A, T, G, C (T/F) 5 8 +3 
13. According to HIPAA, genetic testing results can be used for 
insurance discrimination (T/F) 
8 8 0 
 
Analysis of the pre-survey revealed that the majority of the questions posed had at least a 
62.5% (5/8) correct response rate, with an average correct response rate of 77% (6.15/8). 
Question 3, inquiring about the incidence of hereditary breast cancer in the general population, 
had the lowest correct response rate of 37.5% (3/8). All participants (100%) correctly answered 
questions 6, 10 and 13 on the pre-survey. 
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Analysis of the post-surveys revealed that a gain in knowledge occurred with every 
question (excluding the three questions (6, 10 and 13) that all participants answered correctly on 
the pre-survey), with an average correct response rate of 94% (7.5/8). The questions with the 
greatest gain in knowledge (3, 4 and 12) had an increase in correct responses by 37.5% (+3/8). 
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4.0  DISCUSSION 
This study was designed to document common beliefs about CGS and identify preferred methods 
of communication regarding CGS in the AJ population; in addition, a second goal of the 
information session was to facilitate awareness of CGS. The implications of the study findings 
are vast and with further studies, will aide in the future identification of a preferred service 
delivery model of AJ population-specific genetic counseling with respect to HBOC.  
4.1 AWARENESS OF CGS  
The first aim of the study was to identify the current awareness of CGS in the AJ population. It 
was hypothesized that individuals of AJ ancestry were not aware of cancer genetic counseling or 
testing. Analysis of the surveys completed by study participants revealed that the majority of 
participants were aware of the availability of cancer genetic counseling, with the majority 
stemming from family communication. This understanding allows focus to be placed on the 
preferred method of delivery rather than facilitating awareness of genetic counseling for cancer 
genetics. 
It should be noted that 35.7% of participants reported their prior awareness of CGS due to 
a previous personal experience with genetic counseling, so perhaps individuals attending this 
information session were coming for additional information and the targeted population of those 
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who were unaware did not attend. In addition, it is possible that the individuals who participated 
in the study did so because they had prior awareness of CGS. Perhaps a greater portion of AJ 
individuals than are represented in this study are actually not aware of cancer genetic counseling 
and testing for HBOC and that is why they did not attend the information session.  
 Interestingly, 28.6% of participants reported their prior awareness of CGS was from 
communication with friends, as well as the synagogue. One bias of this study could be that the 
information session was advertised by and held at Rodef Shalom Congregation. Perhaps 
individuals who are affiliated with an institution (like Rodef) may feel a community connection 
to it and would be more inclined to participate in information sessions that were in the 
community setting they were already comfortable with. The results of the information session 
may (or may not) have been different had the information session been hosted at a location that 
has a more sporadic attendance (like a library or an informal meeting hall) instead of regular 
gatherings and a sense of community. 
4.2 BELIEFS REGARDING CGS  
The second aim of the study was to identify any preconceived beliefs (motivations and barriers) 
about CGS. It was hypothesized that the main motivation for AJ individuals to seek CGS was 
perceived high-risk status to develop cancer based on family history or AJ ancestry and survey 
responses were in support of this hypothesis. It was also hypothesized that lack of one’s personal 
knowledge about cancer genetics was the main barrier preventing AJ individuals from obtaining 
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CGS and survey analysis found that the participant’s own perception of lacking knowledge about 
general cancer genetics is a self-identified barrier that is contributing the underutilization of CGS 
in the AJ community. 
Analysis of the pre- and post-session surveys revealed that the information session did 
change the perception of one participant in terms of perceived cancer risk (the individual went 
from feeling neutral risk to feeling low risk). This finding, which supports the idea of AJ 
population-specific genetic counseling, is reminiscent of the Bowen et al., 2006 study, which 
reported that genetic counseling for AJ women of average or moderately increased breast cancer 
risk reduced worry about cancer, lowered inflated perceptions of breast cancer risk and decreased 
interest in having genetic testing.  
When reporting on individual’s perception of cancer risk, it is especially important to 
recognize that an individual’s perception of “high-risk” or “low-risk” based on family history 
can be extremely variable, as seen with the participants of this study. One individual with a 1st-
degree relative with breast and/or ovarian cancer perceived their personal risk as high, while 
another individual with the same family history perceived their risk as low. Another participant 
with a 2nd-degree relative with breast cancer and a 2nd-degree relative with ovarian cancer 
perceived their risk as low, saying “Since I am 76 and my sons are 51 and 49 and our 
grandchildren range from 8 to 12 (all our sons), I haven’t given much thought to genetic testing”. 
Therefore, genetic counseling can provide formal risk assessment and discuss the differences 
between an individuals perception of risk versus calculated risk based on family history.  
Other than personal perceived high-risk status, analysis of the pre- and post-session 
surveys found that the information session did change some opinions of the participants for 
certain perceived benefits. One participant went from feeling neutral to agreeing that knowledge 
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of mutation status would be useful and influence their medical management decisions. Two 
participants went from feeling neutral to agreeing that knowledge of cancer risk status would 
influence their medical management decisions. This finding, an interest in medical management 
decisions, is also important to keep in mind when designing a preferred service delivery model 
for AJ-specific genetic counseling. Because AJ individuals are at an increased risk over the 
general population to carry a BRCA1/2 mutation, emphasizing the different screening, 
chemoprevention and surgical options to help manage cancer risk can empower AJ individuals 
once they know their mutation status (whether positive or negative).  
The information session did change some opinions of the participants for certain 
perceived barriers. One participant went from feeling neutral to disagreeing that the possibility of 
feeling guilty if a gene mutation was passed to their children was a perceived barrier, suggesting 
an increased understanding of the transmission of BRCA mutations (feelings of guilt were 
reduced with the understanding that parents cannot control the genes they pass to their children 
as discussed during the informational portion of the event). Two participants felt like cost was a 
perceived barrier after the information session, suggesting that these individuals were not aware 
of the cost of genetic testing prior to the information session. Two participants went from 
agreeing or feeling neutral to disagreeing that feeling unsure of how to find a genetic counselor 
and lack of genetic information were perceived barriers, suggesting that the information session 
provided adequate information to the participants and helped them feel prepared for seeking 
traditional genetic counseling.  
Analysis of the data from pre- and post-session surveys shows that the majority of AJ 
individuals are aware of cancer genetics and risks associated with their ancestry, but 68.75% of 
participants do not pursue or participate in genetic counseling due to their own perception of 
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lacking knowledge about general cancer genetics. This self-identified barrier is difficult to 
interpret as the average correct response rate of the pre-session survey was 77% and all 
participants (100%) correctly answered questions 6, 10 and 13 on the pre-session survey. The 
high correct response rate on the pre-session survey implies that the participants do not actually 
lack knowledge about general cancer genetics. However, the perception of a lack of knowledge 
is a reported barrier of the participants and is a factor in not seeking CGS.  
The participant’s perception of lacking knowledge about general cancer genetics may 
reflect some form of self-doubt or uncertainty about cancer genetics, or the participants may be 
avoiding seeking CGS for a reason unrelated to “lack of genetic knowledge”. Perhaps the 
emotional impact of testing, in contrast to knowledge about testing, could also be contributing to 
the participant’s self-doubt or uncertainty about cancer genetics. Reasons such as fear of 
knowing actual cancer risk, which was reported as the second main barrier to seeking CGS in 
this study, or fear of knowing test results, which was not reported in this study, could be 
contributing to the participant’s avoidance of CGS. The potential impact of testing or the testing 
process on the entire family, as well as fear of the unknown or issues relating to uncertainty 
rather than genetic knowledge may be a barrier to seeking CGS.  
Finding that the majority of participants do not pursue or participate in genetic counseling 
due to their own perception of lacking knowledge about general cancer genetics may suggest that 
providing education and emotional support in a “nontraditional” setting, reminiscent of the 
Bowen et al., 2006 study, could provide the information necessary for individuals to feel 
prepared to have genetic counseling. Future questionnaires or discussions with individuals in the 
AJ community might elucidate a greater understanding about what information the community 
desires so that this barrier might be removed or better understood. Community-based information 
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sessions, similar to that conducted for this study, may be a good way to provide genetic 
information and emotionally prepare individuals before genetic counseling and therefore 
removing the barrier of the perception of lacking knowledge or fear of knowing test results.  
4.3 PREFERRED COMMUNICATION STRATEGIES 
An additional goal of this study was to identify the preferred method of communicating 
information regarding cancer risks and genetic counseling in the AJ population; assuming that 
discussion with informed relatives would be the preferred method of communication. Contrary to 
what was hypothesized, survey responses revealed that the majority of respondents (75%) felt 
that discussion with a healthcare provider was the best method for communicating information, 
while a minority of respondents (37.5%) obtained this information from their families.  
Knowing that AJ individuals prefer to discuss this information with their health care 
providers suggests that emphasis should be placed on physician education. Physicians should 
also be encouraged to provide their patients with an explanation as to why a referral for CGS is 
appropriate, as well as to provide anticipatory guidance as to what they can expect at their 
appointment. If AJ individuals understand the importance and meaning of CGS when they are 
referred due to “high-risk” status, they may be more inclined to participate.  
The majority (56.25%) of participants reported that their physicians are unaware of their 
AJ ancestry. Ricker et al., 2006, conducted a study that examined the development of a free 
cancer genetics clinic for an underserved, primarily Hispanic population. As part of the 
development of the clinic, 371 participating providers received CME credits for attending five 
educational seminars about genetics and referral guidelines. Surveys revealed that, prior to the 
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seminars; providers answered only 22% of questions correctly. Post seminars, there was a 
documented 94% improvement in knowledge. In addition to the impressive increase in 
knowledge, physicians also began to incorporate this information into practice. Whether 
religious and ethnic background are not routinely obtained in clinic, or AJ individuals did not 
understand the importance of reporting ancestry, continued education within the medical 
community about the importance of discussing family history and AJ ancestry are necessary. The 
themes identified in this study support information from the Ricker study and encourage the idea 
that physician education may be a successful route to take in terms of facilitating communication 
of cancer risk and genetic information between physicians and AJ patients as well as ensuring 
that physicians are making appropriate referrals for genetic counseling.  
During the Question and Answer session, the participants asked many excellent questions 
and provided many relevant personal experiences, the majority of which concerned frustration 
with physicians not discussing individuals increased risk for HBOC due to AJ ancestry. 
Participants seemed confused as to why their physicians never offered them “carrier screening” 
for BRCA1/2 because of their AJ ancestry. 
Due to the AJ founder effect, genetic testing in the AJ population is not a new idea. 
Carrier Screening Programs for recessive diseases like Tay-Sachs disease and Gaucher disease 
(as seen in Table 3) have been common in this community for many years (Charrow, 2004). The 
Jewish community as a whole has embraced the idea of carrier screening, aiming to prevent the 
births of children with genetic disease. It is important to recognize that carrier screening is 
different from disease screening or predisposition screening, which aims to identify individuals 
with a disorder at an early or even pre-symptomatic stage so that the condition can be managed 
more effectively (Charrow, 2004; Levine, 1999).  
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Currently, an evaluation of family history and gene testing are the only options available 
to genetic counselors and physicians to help identify AJ individuals at increased risk to develop 
HBOC-related cancers. To date, BRCA1/2 testing is recommended only for those with a 
convincing family history of HBOC-associated cancer and ideally begins with testing an affected 
family member (NCCN, 2011). Although AJ population-based BRCA testing is currently 
contraindicated outside of a research setting, there have been discussions as to whether this type 
of screening would be appropriate and worthwhile to implement because relying solely on family 
history to predict mutation status can limit interpretation (Rubenstein, 2004; Hartge et al., 1999). 
It should be noted that other preferred methods of communication include exchanges 
between relatives, as well as communication with the synagogue. While information sessions at a 
synagogue would be ideal, it may be beneficial to educate religious officials to mention CGS to 
their congregants and stress the importance of discussing family history and AJ ancestry with 
their healthcare providers. One interesting aspect of this study was that the majority of 
participants identified with Reform Judaism (62.5%). As mentioned before, Orthodox Jews view 
genetic testing for BRCA1/2 mutations as an “obligation” to ones health; however, having a 
known mutation in the family can have substantial consequences for other family member’s 
future marriage prospects. While the reports in the literature regarding Reform and Conservative 
Judaism beliefs are limited, it would be interesting to investigate the beliefs of the other branches 
of Judaism to see if the “obligation” to ones health holds for all branches of Judaism or just the 
Orthodox branch.  
Recalling the Bowen et al., 2003 study that explored the connections between Jewish 
identity and interest in screening behaviors, the finding that cultural identity positively predicted 
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interest in testing whereas religious identity was inversely related is very interesting and 
something that religious officials may want to consider when they explain CGS to their 
congregants. 
4.4 CHANGE IN KNOWLEDGE 
In order to determine the effectiveness of the general genetics discussion, a series of knowledge-
based questions were provided to participants both before the information session and after the 
information session. Gain in knowledge was analyzed by comparing the participant’s answers 
from the pre- and post-session surveys. With an average correct response rate of 77% on pre-
session surveys to 94% on post-session surveys, analysis of the compared surveys proved that 
the information session was an effective tool for educating the AJ population about cancer 
genetics.  
Understanding that communicating genetic information in a group setting outside of a 
hospital facility is an effective method for learning in the AJ population has important 
implications for the future development of a preferred service delivery model of AJ population-
specific genetic counseling. Recalling the results of the Lerman et al., 1999 study, AA women 
had greater intentions to undergo genetic testing for HBOC after receiving informal education in 
addition to traditional genetic counseling, and that same theme was observed in this study.  
This knowledge can encourage genetic counselors to continue to conduct group 
information sessions at synagogues or Jewish community centers, which can facilitate the 
education of many AJ individuals in a condensed period of time, as well as overcome some of 
the barriers to participating in “traditional” genetic counseling. Following an education session, 
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participants may feel better prepared to participate in traditional genetic counseling by already 
having a fundamental cancer genetics background and therefore being able to concentrate on a 
personalized risk assessment, benefits and limitations of testing and potential psychosocial issues 
that are unique to that individual or family. 
4.5 PARTICIPANT AND COMMUNITY FEEDBACK 
The information session was well received by Rodef Shalom Congregation. In addition to the 
large attendance, participants, organizers, synagogue Clergy and the greater community provided 
very positive feedback about the event.  
The individuals who attended the event were attentive throughout the entire session and 
many individuals took notes on the copy of the PowerPoint handout that was provided in the 
attendee’s folders. Participants shared personal stories about their own experiences, asked for 
clarification regarding misconceptions and asked follow-up questions about information in the 
presentation.  
Two individuals provided responses to the open-ended portion of the post-session 
surveys. The surveys requested that participants “share [with us] additional comments regarding 
genetic counseling and testing”. One individual wrote, “Your presentation was great” and the 
other individual wrote, “Great presentation… Well informed, knowledgeable speakers; each of 
whom presented an interesting aspect that led to an overall discussion about Jewish Genetic 
Diseases.”    
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4.6 CONCLUSIONS 
This pilot study was undertaken to aid in the future identification of a preferred service delivery 
model of population-specific genetic counseling for HBOC in the AJ population. The study was 
designed to facilitate awareness of CGS, document common beliefs about CGS and identify 
preferred methods of communication regarding CGS in the AJ population.  
The first aim of the study was to identify the current awareness, as well as facilitate 
awareness, of cancer genetic counseling services in the AJ population in the Pittsburgh area, and 
this aim was achieved. Aim 1 hypothesized that individuals of AJ ancestry were not aware of 
cancer genetic counseling services. The study showed that AJ individuals are aware of cancer 
genetic counseling and testing. Therefore, lack of awareness of CGS in this study population is 
not the main reason for the underutilization of services.  
The second aim of the study was to identify the unique motivations for and perceived 
barriers to AJ individuals obtaining cancer genetic counseling services, and this aim was also 
achieved. Aim 2 hypothesized that personal perception of increased risk to develop cancer based 
on family history or AJ ancestry was the main motivator for seeking cancer genetic counseling 
services, and lack of information about cancer genetics, cancer risk and requirements for genetic 
counseling was the main barrier to obtaining cancer genetic counseling services. The study found 
that the perception of high-risk status to develop cancer based on personal or family history of 
cancer is a significant motivating factor for seeking CGS. The participant’s perception of lacking 
knowledge about general cancer genetics is a self-identified barrier that is contributing to the 
underutilization of CGS in the AJ community.  
The third aim of the study was to identify the preferred methods of communicating 
information about inherited predispositions to cancer to the AJ population, and this aim was 
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achieved as well. Aim 3 hypothesized that individuals of AJ ancestry often have close family 
relationships; therefore, communication between informed relatives may be the preferred 
strategy for promoting cancer genetic services. The study found that AJ individuals prefer that a 
healthcare provider or physician be their main source for information and communication about 
cancer risk, genetic information and referrals for genetics services.  
This study was a collaboration between health care providers and a smaller Jewish 
community organization and received a great amount of community support. Analyzing the 
results of this study and recalling the results of the Lerman et al., 1999 study that revealed that 
AA women had greater intentions to undergo genetic testing for HBOC after receiving informal 
education followed by genetic counseling, encourages the idea that in order to best serve the AJ 
community, an “education plus counseling model,” similar to that proposed for the AA 
population would also be successful for the AJ population.  
The conclusions gained from this study suggest that informal community-based 
information sessions prior to formal or traditional genetic counseling could be a successful 
method to overcoming preconceived perceptions about genetic counseling for this specific 
population. In response to the positive results of this study, additional information sessions 
personalized for the AJ community should be conducted to continue to educate this population 
about AJ-specific cancer genetics. 
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4.7 STUDY LIMITATIONS 
Certain limitations of the study should be noted. The primary limitation of this study was the 
small sample size, which negatively affects the ability to make statistically significant 
conclusions that are applicable to the AJ population as a whole. Because this was a pilot study, 
only 25 participants could be included in the study in accordance with IRB standards for Pilot 
studies.  
The survey response was another limitation impacting the significance of the study. 
While all 25 possible participants agreed to participate in the study, only 16 of them completed 
the pre-session survey even though they were given instructions when they enrolled in the event 
and were encouraged to do so by the genetic counseling intern walking about the room and 
interacting with participants prior to the start of the event. Of those individuals, only 8 completed 
the post-session survey. The option of taking the post-survey home and mailing it back upon 
completion inhibited the return rate. If the participants were not given that option, the response 
rate would likely increase, though many participants were ready to leave at the conclusion of the 
session and some had other obligations to attend. The response rate was further impacted due to 
some participants not answering all of the questions on the surveys.  
It is possible that the location of the information session biased the results of this study. 
The results of the information session may (or may not) have been different had the information 
session been hosted at a location with more sporadic attendance instead of regular gatherings and 
a sense of community like Rodef Shalom Congregation.  
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4.8 FUTURE RESEARCH OPPORTUNITIES 
Given the results of this study, many opportunities exist for future research studies. While this 
study provided insight into the perspectives of AJ individuals with respect to CGS for HBOC, it 
would be useful to investigate additional community-based educational opportunities, as well as 
the perceptions of physicians, other healthcare professionals, and religious officials.  
The study found that the majority of participants do not pursue genetic counseling due to 
their own perception of lacking knowledge about general cancer genetics; however, the high 
correct response rate on the pre-session surveys implies that the participants do not actually lack 
knowledge about general cancer genetics. A future qualitative study investigating the thought 
process and emotional impact of testing, in contrast to knowledge about testing, might help 
elucidate a greater understanding of AJ individual’s perception of lacking knowledge about 
general cancer genetics, and whether or not that perception may reflect some form of self-doubt 
or uncertainty about cancer genetics, or if the participants are avoiding seeking CGS for a reason 
unrelated to “lack of genetic knowledge”. Future qualitative investigations of the AJ population 
regarding the perception of lacking knowledge about general cancer genetics may reveal what 
information the community actually desires so that this barrier might be removed or better 
understood.  
This study found that physicians are the preferred method of communicating cancer risk 
and genetic information in the AJ population. Understanding physician’s current practice of 
obtaining (or not obtaining) their patient’s ethnic background and religious identity in the clinic, 
as well as understanding physician awareness (or lack of awareness) of the importance of 
eliciting a basic family history and recognition of indicators of a hereditary predisposition would 
provide additional insight for conducting future physician-based education programs. Genetic 
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counselors participate and conduct many community, medical and non-medical education 
programs, but perhaps more emphasis should be placed on eliciting ancestry in primary care 
offices and educating about the relationship between the AJ population and HBOC, as well as 
who to refer, how to refer and when to make appropriate referrals for CGS.  
This study found that another method of preferred communication involved synagogues. 
While this study proved that information sessions at synagogues are well received, there may be 
future educational opportunities at Jewish Community Centers, perhaps mirroring the 
information sessions at synagogues. Conducting information sessions on a larger scale, like that 
of a community center, would help to determine success and interest in large scale community-
based cancer genetics educational programs. 
Future religious official-based education programs may be helpful for clergy members 
regarding how to discuss genetic topics with their congregants, how to explain the importance of 
discussing cancer history with family members and how to explain the importance of discussing 
AJ ancestry with physicians. Religious official-based education programs may also provide the 
opportunity for genetic counselors and clergy members to discuss the Jewish perspective (of all 
branches of Judaism) on genetic testing for hereditary cancer predispositions and the 
implications for the individual and family, providing invaluable insight and feedback for genetic 
counselors designing a preferred service delivery model for AJ individuals.  
The conclusions gained from this study provide suggestions that could lead to a 
successful method to overcoming preconceived perceptions about genetic counseling for the AJ 
population. 
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APPENDIX A: DIFFERENTIAL DIAGNOSIS  
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Other than HBOC, the most significant hereditary cancer syndromes leading to an increased risk 
for breast cancer include Li-Fraumeni syndrome (LFS), Cowden syndrome and Peutz-Jeghers 
syndrome (PJS). LFS, caused by mutations in p53, increases the risk for multiple types of cancer, 
including: breast cancer, soft tissue sarcomas, osteosarcomas, leukemia, adrenocortical 
carcinomas and brain tumors (Malkin, 2011). Cowden syndrome, caused by mutations in PTEN, 
is associated with an increased risk for breast cancer, uterine cancer and thyroid cancer. Cowden 
syndrome is also associated with characteristic benign harmatomatous lesions of the skin, oral 
mucosa and intestinal mucosa, as well as benign breast and thyroid disease (Eng, 2000; 
Trepanier et al., 2004). PJS, caused by mutations in STK11/LKB1, is associated with an 
increased risk for breast cancer, pancreatic cancer, prostate cancer and benign ovarian tumors. 
PJS is also associated with characteristic benign harmatomatous polyps of the GI tract, ureter, 
bladder, renal pelvis, bronchus and nasal passage, as well as melanin spots on the lips, oral 
mucosa and fingers (Trepanier et al., 2004). 
Lynch syndrome accounts for approximately 7% of hereditary predispositions to ovarian 
cancer. Lynch syndrome, also known as Hereditary Non-polyposis Colorectal Cancer (HNPCC), 
is caused by mutations in one of several genes, including: MLH1, MSH2, MSH6, PMS2 and 
EPCAM. Lynch syndrome increases the risk for colon cancer, uterine cancer, ovarian cancer, 
small bowel cancer, gastric cancer, pancreas cancer, ureter cancer and renal pelvis cancer 
(Lynch, 2000).  
 68 
APPENDIX B: LETTERS OF IRB APPROVAL 
 
 
 
 
 
 
 
 
 
 69 
 
 70 
 
 71 
APPENDIX C: ADVERTISEMENTS 
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Jewish Genetic Disease Program: What you need to know! 
AGENDA 
 
 
Rodef Shalom Synagogue  
December 11, 2011        10:00-11:30am 
Room: ALC1 
 
Guest speakers 
Barbara and Jay Rogal 
Kathy Pattak  
 
Presenter 
Rachel Pearlman 
 
Panel 
Rachel Pearlman 
Megan Marshall 
Rabbi Hertz 
Barbara and Jay Rogal 
 
 
 
10:00am Introduction/Welcome         Rabbi Amy Hertz 
    
10:05am Guest Speakers            Barbara and Jay Rogal     
  -The Rogals will share their personal experience with Jewish Genetic   
     Diseases and speak about the screenings they help organize in PGH 
 
10:20am Guest Speaker        Kathy Pattak 
-Kathy will share her personal experiences with genetic counseling  
 and testing for hereditary breast and ovarian cancer    
   
10:35am Hereditary Breast and Ovarian Cancer presentation     Rachel Pearlman 
   -Rachel will discuss the difference between hereditary and sporadic  
cancer, hereditary breast and ovarian cancer in the Ashkenazi Jewish   
population, medical management options and genetic testing   
 
11:10am Q/A, summary panel   
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CANCER GENETICS PROGRAM 
WEST PENN ALLEGHENY HEALTH SYSTEM 
 
Pre-Cancer Genetics Information Session Survey 
 
Date:     /     /        CG ID# 
 
Please answer the following cancer genetics questions to the best of your knowledge. 
 
Demographics questions: 
 
The following questions tell us more about you.  Please circle or fill in the answer that best describes you. 
 
1. Sex:  M     F 
 
 
2. I am ____years old:  18-25     25-30     31-40     40-50     50-60     60-70     70+ 
 
 
3. I am _____: Single  Married Divorced  Widowed In a relationship 
 
 
4. I have _____children: 0 1 2 3 4 5+ 
 
 
5. The highest level of school I have finished is ____ :  Some high school    
          High School graduate    
             Some college     
          College graduate    
          Graduate/professional school 
 
6. Religious Affiliation:  Reform      Conservative      Orthodox      Jewish      Other__    None____ 
 
 
7. Do you belong to a synagogue?     Yes ____   No ____     
 
 
8. Have you ever participated in genetic counseling?          Yes ____   No ____     I don’t know____      
 
 
9. Have you ever participated in genetic testing?    Yes ____   No ____     I don’t know____      
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Family history questions: 
 
1. Do you consider yourself to be an individual of Ashkenazi Jewish ancestry? Yes ____   No ____     
 
 
2. What country are your ancestors from? 
 
 
3. Have any of your close relatives been diagnosed with cancer?   Yes ____   No ____     
 
Type: 
 
a. Breast  
b. Ovarian 
c. Colon 
d. Pancreatic 
e. Melanoma 
f. Other: ___ 
 
How are you related? 
 
4. Have any of your close relatives been diagnosed with cancer before age 50?    Yes ____   No ____     
 
How are you related? 
 
5. Have you ever been diagnosed with cancer?   Yes ____   No ____     
Type: 
 
a. Breast  
b. Ovarian 
c. Colon 
d. Pancreatic 
e. Melanoma 
f. Other: ___ 
 
6. Were you diagnosed before age 50?    Yes ____   No ____     
 
 
The following are questions about hereditary breast-ovarian cancer. Please read each question 
carefully and circle the BEST answer for each question. 
 
 
1. True or False  The majority of all cancer is hereditary 
 
2. How common is breast cancer in the general population?  
1 in 8  1 in 40  1 in 100 1 in 800 
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3. How common is hereditary breast cancer in the general population?  
1 in 8  1 in 40  1 in 100 1 in 800 
 
 
4. How common is hereditary breast cancer in individuals of Ashkenazi Jewish ancestry?                          
1 in 8  1 in 40  1 in 100 1 in 800 
 
5. True or False      Cancer is only passed through your mother (mother’s side of the family) 
 
6. True or False  Having a cancer gene means you will definitely develop cancer 
 
7. True or False  Inheriting a mutation (change) in a cancer gene increases the risk that 
   you will develop specific types of cancer 
 
8. How many genes must someone inherit to have Hereditary Breast-Ovarian Cancer?                             
a. Zero, it is not caused by genes                 b. One from mom          c. One from mom or dad           
d. Two, one from mom and one from dad    e. None of the above  
 
 
9. How can you tell if someone carries a gene that puts them at an increased risk for Hereditary 
Breast-Ovarian Cancer?      
a. They look sick b. They have been diagnosed with breast and/or ovarian cancer    
c. With a simple blood test d. There is no way to know e. None of the above   
         
      
10. True or False  If a person has genetic testing and no mutation is found in their cancer 
   genes, that person will never develop cancer 
 
11. True or False  A mutation in a breast cancer gene also contributes to a higher risk of 
   ovarian cancer 
 
12. True or False  Our genetic code (DNA) consists of A, C, T, G 
 
13. True or False   According to HIPAA (Health Information Portability and Accountability 
   Act), genetic testing results can be used for insurance discrimination 
 
14.  What do you believe is your estimated risk of cancer (1 to 10, with 10 being the highest)? _____ 
 
Communication questions: 
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1. What method is the best way to communicate information about cancer risk and family history? 
___Health care provider 
___Relative 
___Friend 
___Newspaper/magazine 
___Internet 
___Synagogue/religious organization 
___Other:_____________________   
 
2. Do you think healthcare professionals are aware of your Ashkenazi Jewish ancestry when 
discussing health issues, especially relating to cancer? 
 
 
Health belief questions: 
 
For the following questions, please tell us whether you: 
 
5. STRONGLY AGREE 
4. AGREE 
3. NEUTRAL 
2. DISAGREE 
1. STRONGLY DISAGREE 
 
Severity 
 
1. Hereditary Breast-Ovarian Cancer is a serious disease_____ 
 
2. I think passing a gene mutation to my children would be scary_____ 
 
3. My life would change if I had a gene mutation that predisposed me to Hereditary Breast-Ovarian 
Cancer_____ 
 
Susceptibility 
 
1. I feel I am at risk for developing Hereditary Breast-Ovarian Cancer_____ 
 
2. There is a genetic cause to the cancers in my family_____ 
 
3. I carry a genetic susceptibility to Hereditary Breast-Ovarian Cancer_____ 
 
Benefit 
 
1. It is useful to know whether I have an increased risk to develop breast or ovarian cancer_____ 
 
2. It is useful to know whether I have a gene mutation that causes an increased risk to develop breast 
or ovarian cancer_____ 
 
3. Knowing the risk of developing breast or ovarian cancer would change my medical 
management_____ 
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Barriers 
 
1. Testing for a gene mutation known to cause breast and/or ovarian cancer is painful and 
difficult_____ 
 
2. Testing for a gene mutation known to cause breast and/or ovarian cancer would increase my 
anxiety and make me worry about other family members_____ 
 
3. Testing for a gene mutation known to cause breast and/or ovarian cancer would make me feel 
guilty if my children were found to inherit the gene mutation_____ 
 
4. I would not want to pay for genetic testing if it is not paid for by my insurance_____ 
 
5. I do not know how to find a genetic counselor in my area_____ 
 
6. I am worried about health insurance, life insurance and job discrimination_____ 
 
7. I would feel ashamed, singled-out and/or viewed negatively in my community if I participated in 
genetic testing_____ 
 
8. I think fear of knowing cancer risk is a block to genetic counseling for breast cancer______ 
 
9. I think lack of genetic information is a block to genetic counseling for breast cancer______ 
 
10. I think not knowing family history is a block to genetic counseling for breast cancer______ 
 
11. This information would provide a benefit to my family and me______ 
 
12. I know how to find more information______ 
 
 
 
Please share with us additional comments regarding genetic counseling and testing that were not 
addressed in the questions above. 
 
 
 
 
 
 
 
 
 
 
Thank you for taking the time to complete this survey. If you have questions regarding the 
survey, the study, or for additional information, please call (412) 359-8064. 
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APPENDIX G: INFORMATION SESSION POWERPOINT 
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APPENDIX H: POST-SESSION SURVEY 
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CANCER GENETICS PROGRAM 
WEST PENN ALLEGHENY HEALTH SYSTEM 
 
Post-Cancer Genetics Information Session Survey 
 
Date:     /     /        CG ID# 
 
Please answer the following cancer genetics questions to the best of your knowledge. 
 
Questionnaire for assessment of knowledge of Cancer Genetics: 
 
The following are questions about hereditary breast-ovarian cancer. Please read each question 
carefully and circle the BEST answer for each question. 
 
 
1. True or False  The majority of all cancer is hereditary 
 
2.   How common is breast cancer in the general population?  
1 in 8  1 in 40  1 in 100 1 in 800 
 
 
      3.    How common is hereditary breast cancer in the general population?  
1 in 8  1 in 40  1 in 100 1 in 800 
 
 
4. How common is hereditary breast cancer in individuals of Ashkenazi Jewish ancestry?                    
1 in 8  1 in 40  1 in 100 1 in 800     
  
5.  True or False      Cancer is only passed through your mother (mother’s side of the family) 
 
6. True or False  Having a cancer gene means you will definitely develop cancer 
 
7. True or False  Inheriting a mutation (change) in a cancer gene increases the risk that 
   you will develop specific types of cancer 
 
8. How many genes must someone inherit to have Hereditary Breast-Ovarian Cancer?                             
a. Zero, it is not caused by genes                 b. One from mom          c. One from mom or dad           
d. Two, one from mom and one from dad    e. None of the above  
 
 
9. How can you tell if someone carries a gene that puts them at an increased risk for Hereditary 
Breast-Ovarian Cancer?      
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a. They look sick b. They have been diagnosed with breast and/or ovarian cancer    
c. With a simple blood test d. There is no way to know e. None of the above   
         
      
10. True or False  If a person has genetic testing and no mutation is found in their cancer 
   genes, that person will never develop cancer 
 
11. True or False  A mutation in a breast cancer gene also contributes to a higher risk of 
   ovarian cancer 
 
12. True or False  Our genetic code (DNA) consists of A, C, T, G 
 
13. True or False   According to HIPAA (Health Information Portability and Accountability 
   Act), genetic testing results can be used for insurance discrimination 
 
14.  What do you believe is your estimated risk of cancer (1 to 10, with 10 being the highest)? _____ 
 
Communication questions: 
 
1. What method is the best way to communicate information about cancer risk and family history? 
___Health care provider 
___Relative 
___Friend 
___Newspaper/magazine 
___Internet 
___Synagogue/religious organization 
___Other:_____________________   
 
2. Do you think healthcare professionals are aware of your Ashkenazi Jewish ancestry when 
discussing health issues, especially relating to cancer? 
 
 
Health belief questions: 
 
For the following questions, please tell us whether you: 
 
5. STRONGLY AGREE 
4. AGREE 
3. NEUTRAL 
2. DISAGREE 
1. STRONGLY DISAGREE 
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Severity 
 
1.    Hereditary Breast-Ovarian Cancer is a serious disease_____ 
2.    I think passing a gene mutation to my children would be scary_____ 
3.    My life would change if I had a gene mutation that predisposed me to Hereditary Breast-Ovarian
 Cancer_____ 
 
Susceptibility 
 
1.    I feel I am at risk for developing Hereditary Breast-Ovarian Cancer_____  
2.    There is a genetic cause to the cancers in my family_____ 
3.    I carry a genetic susceptibility to Hereditary Breast-Ovarian Cancer_____ 
 
Benefit 
 
1.    It is useful to know whether I have an increased risk to develop breast or ovarian cancer_____  
2.  It is useful to know whether I have a gene mutation that causes an increased risk to develop breast  
or ovarian cancer _____ 
 
3. Knowing the risk of developing breast or ovarian cancer would change my medical 
management_____ 
 
Barriers 
 
1.   Testing for a gene mutation known to cause breast and/or ovarian cancer is painful and difficult  
_____  
 
2.  Testing for a gene mutation known to cause breast and/or ovarian cancer would increase my
 anxiety and make me worry about other family members _____ 
 
3.  Testing for a gene mutation known to cause breast and/or ovarian cancer would make me feel
 guilty if my children were found to inherit the gene mutation _____ 
 
4. I would not want to pay for genetic testing if it is not paid for by my insurance_____  	  
5.    I do not know how to find a genetic counselor in my area _____ 
 
6.  I am worried about health insurance, life insurance and job discrimination _____ 
 
7.    I would feel ashamed, singled-out and/or viewed negatively in my community if I participated in
 genetic testing _____  
 
8.    I think fear of knowing cancer risk is a block to genetic counseling for breast cancer _____ 
 
9.    I think lack of genetic information is a block to genetic counseling for breast cancer _____ 
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10.  I think not knowing family history is a block to genetic counseling for breast cancer _____  
 
11.  This information would provide a benefit to my family and me _____ 
 13. I	  know	  how	  to	  find	  more	  information	  _____	  
 
 
 
 
 
Please share with us additional comments regarding genetic counseling and testing that were not 
addressed in the questions above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for taking the time to complete this survey. If you have questions regarding the 
survey, the study, or for additional information, please call (412) 359-8064. 
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